

Patent Trial and Appeal Case Tracking System (P-TACTS)

Case # [IPR2023-00724 \(original\)](#) TRIAL INSTITUTED
Patent # [10335462](#)

Parties Mylan Pharmaceuticals Inc. et al. v. Novo Nordisk A/S

Tech center 1600 Art unit 1654

[AIA review information](#) [Motions](#) [Rehearing requests](#) [Notices of appeal](#)

Expand all | Collapse all

Documents & claims

Documents

Claims

Updated: 06/11 3:23PM



Papers

Next available paper # 63

All (62) Board (10) Petitioner (26) Patent Owner / Respondent (26)



✓	Paper #	Filing date	Paper type	Document name	Pages	Filing party	Availability
✓	62	06/10/2024	Notice: Notice of deposition	Notice of Deposition of Dr. Allen Spiegel	8	Patent Owner	Public
✓	61	06/10/2024	Notice: Notice of deposition	Notice of Deposition of Arthur Z. Schwartzbard, M.D.	8	Patent Owner	Public
✓	60	06/10/2024	Notice: Notice of deposition	Notice of Deposition of DeForest McDuff, Ph.D.	8	Patent Owner	Public
✓	59	06/10/2024	Notice: Notice of deposition	Notice of Deposition of William J. Jusko, Ph.D.	8	Patent Owner	Public
✓	58	06/10/2024	Notice: Notice of deposition	Notice of Deposition of Steven G. Coca, D.O., M.S.	8	Patent Owner	Public
✓	57	06/10/2024	Notice: Notice of deposition	Notice of Deposition of Dr. John Bantle	8	Patent Owner	Public
✓	56	06/07/2024	Other: other	June 7, 2024 Joint Stipulation to Modify Due Dates 3, 4, 5, 6, 7 and 8	7	Patent Owner	Public
✓	55	05/30/2024	Other: other	Patent Owner's Objections to Evidence	14	Patent Owner	Public
✓	54	05/28/2024	Notice: Other	Institution decision and grant of joinder, IPR2024-00107	17	Board	Public
✓	53	05/22/2024	Pet Reply to PO Resp	Petitioner's Reply (Protective Order Material)	54	Petitioner	Parties and Board
✓	52	05/22/2024	Notice: Exhibit list	Updated List of Petitioner's Exhibits	29	Petitioner	Public
✓	51	05/22/2024	Motion: Other	Petitioner's Motion to Seal	4	Petitioner	Public
✓	50	04/25/2024	Other: other	Certificate of Service for Corrected Exhibit 2110	4	Patent Owner	Public
✓	49	04/25/2024	Notice: Other	Institution decision and grant of joinder, IPR2024-00009	16	Board	Public
✓	48	04/16/2024	Notice: Notice of deposition	Petitioner's Notice of Deposition of Dr. Julie Rosenstock	3	Petitioner	Public

✓	Paper # ↓	Filing date	Paper type	Document name	Pages	Filing party	Availability
✓	47	04/16/2024	Other: other	Joint Stipulation to Modify Due Dates 2, 3, 4, 5, 6, 7 and 8	4	Petitioner	Public
✓	46	04/10/2024	Notice: Exhibit list	Patent Owner's Updated Exhibit List	23	Patent Owner	Public
✓	45	04/01/2024	Notice: Updated Mandatory Notice	Petitioner's Updated Mandatory Notices	5	Petitioner	Public
✓	44	04/01/2024	Notice: Power of Attorney	Petitioner's Updated Power of Attorney	4	Petitioner	Public
✓	43	03/29/2024	Notice: Notice of deposition	Petitioner's Notice of Deposition of Dr. Christopher A. Velturo	3	Petitioner	Public
✓	42	03/29/2024	Notice: Notice of deposition	Petitioner's Notice of Deposition of Dr. Patrick J. Sinko	3	Petitioner	Public
✓	41	03/29/2024	Notice: Notice of deposition	Petitioner's Notice of Deposition of Dr. Robin S. Goland	3	Petitioner	Public
✓	40	03/29/2024	Notice: Notice of deposition	Petitioner's Notice of Deposition of Michael J. Blaha	3	Petitioner	Public
✓	39	03/29/2024	Notice: Notice of deposition	Petitioner's Notice of Deposition of Dr. George L. Bakris	3	Petitioner	Public
✓	38	03/20/2024	Order: Other	ORDER Granting Patent Owner's Motions for Admission Pro Hac Vice of Jenny C. Wu and Philip S. May 37 C.F.R. § 42.10	4	Board	Public
✓	37	03/13/2024	Notice: Updated Mandatory Notice	Patent Owner's Second Supplemental Mandatory Notices	8	Patent Owner	Public
✓	36	03/12/2024	Order: on Motion	ORDER Conditionally Granting Patent Owner's Motions for Admission Pro Hac Vice of Jenny C. Wu and Philip S. May 37 C.F.R. § 42.10	4	Board	Public
✓	35	03/06/2024	Motion: PHV	Patent Owner's Unopposed Motion for Pro Hac Vice Admission of Philip S. May	27	Patent Owner	Public
✓	34	03/06/2024	Motion: PHV	Patent Owner's Unopposed Motion for Pro Hac Vice Admission of Jenny C. Wu	27	Patent Owner	Public
✓	33	03/06/2024	Notice: Notice of deposition	Petitioner's Notice of Deposition of Christine Jensen	3	Petitioner	Public
✓	32	03/06/2024	Notice: Notice of deposition	Petitioner's Notice of Deposition of Anne Flint	3	Petitioner	Public
✓	31	01/24/2024	Other: other	Petitioner's Objections to Patent Owner's Evidence	36	Petitioner	Public
✓	30	01/17/2024	PO Response to Pet	Patent Owner's Response [REDACTED]	122	Patent Owner	Public
✓	29	01/17/2024	PO Response to Pet	Patent Owner's Response [SEALED]	122	Patent Owner	Parties and Board
✓	28	01/17/2024	Motion: Other	Novo Nordisk A/S's Motion to Seal and for Entry of a Protective Order	11	Patent Owner	Public
✓	27	01/09/2024	Order: on Motion	ORDER Conduct of the Proceeding 37 C.F.R. § 42.5	3	Board	Public
✓	26	01/08/2024	Order: on Motion	ORDER Granting Petitioner's Motions for Pro Hac Vice Admission of Shannon M. Bloodworth, David L. Anstaett, and Bryan D. Beel 37 C.F.R. § 42.10	4	Board	Public
✓	25	12/28/2023	Notice: Updated Mandatory Notice	Patent Owner's Supplemental Mandatory Notice	5	Patent Owner	Public

✓	Paper # ↓	Filing date	Paper type	Document name	Pages	Filing party	Availability
✓	24	12/26/2023	Order: on Motion	ORDER Conduct of the Proceeding 37 C.F.R. § 42.5	4	Board	Public
✓	23	12/18/2023	Notice: Updated Mandatory Notice	Petitioner's Updated Mandatory Notices	5	Petitioner	Public
✓	22	12/18/2023	Notice: Power of Attorney	Petitioner's Updated Power of Attorney	4	Petitioner	Public
✓	21	12/18/2023	Notice: Exhibit list	Updated List of Petitioner's Exhibits	10	Petitioner	Public
✓	20	12/18/2023	Motion: PHV	Motion for Pro Hac Vice Admission of Bryan D. Beel	4	Petitioner	Public
✓	19	12/18/2023	Motion: PHV	Motion for Pro Hac Vice Admission of David L. Anstaett	4	Petitioner	Public
✓	18	12/18/2023	Motion: PHV	Motion for Pro Hac Vice Admission of Shannon M. Bloodworth	4	Petitioner	Public
✓	17	12/15/2023	Notice: Notice of deposition	Notice of Deposition of Paul Dalby, Ph.D.	5	Patent Owner	Public
✓	16	12/15/2023	Notice: Notice of deposition	Notice of Deposition of William J. Jusko, Ph.D.	5	Patent Owner	Public
✓	15	12/15/2023	Notice: Notice of deposition	Notice of Deposition of John Bantle, M.D.	5	Patent Owner	Public
✓	14	11/09/2023	Other: other	November 9, 2023 Joint Stipulation to Modify Due Dates 1, 2, 3, 5 & 6	4	Patent Owner	Public
✓	13	10/19/2023	Other: other	Petitioner's Objections to Patent Owner's Exhibits	6	Petitioner	Public
✓	12	10/18/2023	Other: other	Patent Owner's Objections to Evidence	9	Patent Owner	Public
✓	11	10/04/2023	Order: Other	SCHEDULING ORDER	12	Board	Public
✓	10	10/04/2023	Institution Decision: Grant	Institution Decision: Grant	41	Board	Public
✓	9	08/17/2023	Other: other	Patent Owner's Sur-Reply to Petitioner's Reply to Patent Owner's Preliminary Response	8	Patent Owner	Public
✓	8	08/10/2023	Notice: Exhibit list	Updated List of Petitioner's Exhibits	10	Petitioner	Public
✓	7	08/10/2023	Pet Reply to PO Resp	Petitioner's Reply to Patent Owner's Preliminary Response	10	Petitioner	Public
✓	6	07/06/2023	POPR: filed	Patent Owner's Preliminary Response	80	Patent Owner	Public
✓	5	04/06/2023	Notice: Notice filing date accorded	Notice: Notice filing date accorded	5	Board	Public
✓	4	04/06/2023	Notice: Mandatory Notice	Patent Owner's Mandatory Notices	6	Patent Owner	Public
✓	3	04/06/2023	Notice: Power of Attorney	Power of Attorney and Designation of Lead and Back-Up Counsel	6	Patent Owner	Public
✓	2	03/16/2023	Notice: Power of Attorney	Notice : Power of Attorney	3	Petitioner	Public
✓	1	03/16/2023	Petition: as filed	Petition : as filed	86	Petitioner	Public

Exhibits

All (644)
 1000s (313)
 2000s (328)
 3000s (3)

T (0)

Exhibit # ↓	Filing date	Document name	Pages	Filing party	Availability	
✓						
✓	3003	12/26/2023	Email from: Megan Raymond To: Trials Cc: white-ptabReel, Bryan D. greb-ptab prochnowptab jones-ptab tietz-ptab lembo-ptab; Novo-Semaglutide Subject: IPR2023-00724 Date, December 15, 2023	1	Board	Public
✓	3002	11/29/2023	Exhibit 3002	3	Board	Public
✓	3001	08/03/2023	Exhibit 3001	2	Board	Public
✓	2535	04/10/2024	EX2535 - Declaration of Jenny C. Wu	4	Patent Owner	Public
✓	2534	03/06/2024	EX2534 - Declaration of Philip S. May	4	Patent Owner	Public
	2533	03/06/2024	EX2533 - Declaration of Jenny C. Wu	4	Patent Owner	Public
✓	2533	01/17/2024	EX2533 - Novo Nordisk seeks partners within	4	Patent Owner	Public
✓	2532	01/17/2024	EX2532 - Synjardy and Synjardy XR Prescribing Information (rev. Oct. 2023)	48	Patent Owner	Public
✓	2531	01/17/2024	EX2531 - Invokamet and Invokamet XR Prescribing Information (rev. July 2023)	60	Patent Owner	Public
✓	2530	01/17/2024	EX2530 - Janumet XR Prescribing Information (rev. Feb. 2012)	34	Patent Owner	Public
✓	2529	01/17/2024	EX2529 - Eli Lilly & Co., Income Statements for Year Ending 2019 to 2022, https://investor.lilly.com/financial-information/fundamentals/income-statement, last visited Jan. 14, 2024	37	Patent Owner	Public
✓	2528	01/17/2024	EX2528 - Eli Lilly & Co., SEC Form 10-Q for the Quarter Ended March 31, 2023 (Apr. 27, 2023)	48	Patent Owner	Public
✓	2527	01/17/2024	EX2527 - Eli Lilly & Co., SEC Form 10-Q for the Quarter Ended June 30, 2023 (Aug. 8, 2023)	53	Patent Owner	Public
✓	2526	01/17/2024	EX2526 - Eli Lilly & Co., SEC Form 10-Q for the Quarter Ended September 30, 2023 (Nov. 2, 2023)	52	Patent Owner	Public
✓	2525	01/17/2024	EX2525 - Eli Lilly & Co., 2018 Financial Report	186	Patent Owner	Public
✓	2524	01/17/2024	EX2524 - Eli Lilly & Co., 2019 Financial Report	187	Patent Owner	Public
✓	2523	01/17/2024	EX2523 - Eli Lilly & Co., SEC Form 10-K for the Year Ended December 31, 2022 (Feb. 22, 2023)	178	Patent Owner	Public
✓	2522	01/17/2024	EX2522 - Novo Nordisk, "Ozempic (semaglutide) injection 0.5 mg, 1 mg, or 2 mg; WAC Price," https://www.novopricing.com/ozempic.html, last updated Oct. 2023	1	Patent Owner	Public
✓	2521	01/17/2024	EX2521 - Bibeau, W.S., et al., Impact of Out-of-Pocket Pharmacy Costs on Branded Medication Adherence Among Patients with Type 2 Diabetes, J. Manag. Care Spec. Pharm., 2016 Nov; 22(11):1338-1347	11	Patent Owner	Public
✓	2520	01/17/2024	EX2520 - NYU Langone Health, "Medication for Type 2 Diabetes," https://nyulangone.org/conditions/type-2-diabetes/treatments/medication-for-type-2-diabetes	9	Patent Owner	Public
✓	2519	01/17/2024	EX2519 - Gorgjo-Martínez, J.J., et al., Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus, J. Clin. Med., 2023 Jan; 12(1):145	17	Patent Owner	Public
✓	2518	01/17/2024	EX2518 - Han, S.H., et al., Public Interest in the Off-Label Use of Glucagon-like Peptide 1 Agonists (Ozempic) for Cosmetic Weight Loss: A Google Trends Analysis, Aesthetic Surgery J., 2024 Jan; 44(1):60-67	8	Patent Owner	Public
✓	2517	01/17/2024	EX2517 - Merck Provides Update on Combination Medicine JUVISYNCRTM (sitagliptin and simvastatin) Tablets, https://www.merck.com/news/merck-provides-update-on-combination-medicine-juvisync-sitagliptin-and-simvastatin-tablets (Sept. 26, 2013)	3	Patent Owner	Public
✓	2516	01/17/2024	EX2516 - Novo Nordisk, Financial report for the period 1 January 2023 to 30 September 2023 (Nov. 2, 2023)	34	Patent Owner	Public
✓	2515	01/17/2024	EX2515 - Novo Nordisk, Financial report for the period 1 January 2023 to 30 June 2023 (Aug. 10, 2023)	32	Patent Owner	Public
✓	2514	01/17/2024	EX2514 - Novo Nordisk, Financial report for the period 1 January 2023 to 31 March 2023 (May 4, 2023)	29	Patent Owner	Public
✓	2513	01/17/2024	EX2513 - Novo Nordisk, Financial report for the period 1 January 2022 to 31 December 2022 (Feb. 1, 2023)	33	Patent Owner	Public

✓	Exhibit # ↓	Filing date	Document name	Pages	Filing party	Availability
✓	2512	01/17/2024	EX2512 - Novo Nordisk, Financial report for the period 1 January 2022 to 30 September 2022 (Nov. 2, 2022)	32	Patent Owner	Public
✓	2511	01/17/2024	EX2511 - Novo Nordisk, Financial report for the period 1 January 2022 to 30 June 2022 (Aug. 3, 2022)	34	Patent Owner	Public
✓	2510	01/17/2024	EX2510 - Novo Nordisk, Financial report for the period 1 January 2022 to 31 March 2022 (Apr. 29, 2022)	29	Patent Owner	Public
✓	2509	01/17/2024	EX2509 - Novo Nordisk, Financial report for the period 1 January 2021 to 31 December 2021 (Feb. 2, 2022)	33	Patent Owner	Public
✓	2508	01/17/2024	EX2508 - Novo Nordisk, Financial report for the period 1 January 2021 to 30 September 2021 (Nov. 3, 2021)	30	Patent Owner	Public
✓	2507	01/17/2024	EX2507 - Novo Nordisk, Financial report for the period 1 January 2021 to 30 June 2021 (Aug. 4, 2021)	31	Patent Owner	Public
✓	2506	01/17/2024	EX2506 - Novo Nordisk, Financial report for the period 1 January 2021 to 31 March 2021 (May 5, 2021)	26	Patent Owner	Public
✓	2505	01/17/2024	EX2505 - Novo Nordisk, Financial report for the period 1 January 2020 to 31 December 2020 (Feb. 3, 2021)	36	Patent Owner	Public
✓	2504	01/17/2024	EX2504 - Novo Nordisk, Financial report for the period 1 January 2020 to 30 September 2020 (Oct. 30, 2020)	33	Patent Owner	Public
✓	2503	01/17/2024	EX2503 - Novo Nordisk, Financial report for the period 1 January 2020 to 30 June 2020 (Aug. 6, 2020)	31	Patent Owner	Public
✓	2502	01/17/2024	EX2502 - Novo Nordisk, Financial report for the period 1 January 2020 to 31 March 2020 (May 6, 2020)	29	Patent Owner	Public
✓	2501	01/17/2024	EX2501 - Novo Nordisk, Financial report for the period 1 January 2019 to 31 December 2019 (Feb. 5, 2020)	34	Patent Owner	Public
✓	2500	01/17/2024	EX2500 - Novo Nordisk, Financial report for the period 1 January 2019 to 30 September 2019 (Nov. 1, 2019)	28	Patent Owner	Public
✓	2499	01/17/2024	EX2499 - Novo Nordisk, Financial report for the period 1 January 2019 to 30 June 2019 (Aug. 9, 2019)	30	Patent Owner	Public
✓	2498	01/17/2024	EX2498 - Novo Nordisk, Financial report for the period 1 January 2019 to 31 March 2019 (May 3, 2019)	28	Patent Owner	Public
✓	2497	01/17/2024	EX2497 - Novo Nordisk, Financial report for the period 1 January 2018 to 31 December 2018 (Feb. 1, 2019)	36	Patent Owner	Public
✓	2496	01/17/2024	EX2496 - Novo Nordisk, Financial report for the period 1 January 2018 to 30 September 2018 (Nov. 1, 2018)	31	Patent Owner	Public
✓	2495	01/17/2024	EX2495 - Novo Nordisk, Financial report for the period 1 January 2018 to 30 June 2018 (Aug. 8, 2018)	30	Patent Owner	Public
✓	2494	01/17/2024	EX2494 - Novo Nordisk, Financial report for the period 1 January 2018 to 31 March 2018 (May 2, 2018)	29	Patent Owner	Public
✓	2488	01/17/2024	EX2488 - U.S. Patent No. 8,536,122	70	Patent Owner	Public
✓	2487	01/17/2024	EX2487 - U.S. Patent No. 8,129,343	72	Patent Owner	Public
✓	2486	01/17/2024	EX2486 - U.S. Food & Drug Administration, Drugs@FDA, Avandia	5	Patent Owner	Public
✓	2485	01/17/2024	EX2485 - U.S. Food & Drug Administration, Drugs@FDA, Actos	9	Patent Owner	Public
✓	2484	01/17/2024	EX2484 - IMS Institute for Healthcare Informatics, "Price Declines after Branded Medicines Lose Exclusivity in the U.S." (Jan. 2016), available at https://www.igvia.com/-/media/igvia/pdfs/institute-reports/price-declines-after-branded-medicines-lose-exclusivity-in-the-us.pdf	7	Patent Owner	Public
✓	2483	01/17/2024	EX2483 - IOVIA, "Available IOVIA Data," https://www.igvia.com/insights/the-igvia-institute/available-igvia-data	4	Patent Owner	Public
✓	2482	01/17/2024	EX2482 - Novo Nordisk, "Possible Side Effects of Ozempic (semaglutide) Injection," https://www.ozempic.com/how-to-take/side-effects.html	4	Patent Owner	Public
✓	2482	01/17/2024	EX2482 - Novo Nordisk, "Possible Side Effects of Ozempic® (semaglutide) Injection," https://www.ozempic.com/how-to-take/side-effects.html	4	Patent Owner	Public
✓	2481	01/17/2024	EX2481 - "FDA Approves Ozempic (semaglutide) for Cardiovascular Risk Reduction in Adults with Type 2 Diabetes and Known Heart Disease," https://www.drugs.com/newdrugs/fda-approves-ozempic-semaglutide-cardiovascular-risk-reduction-adults-type-2-diabetes-known-heart-5143.html (Jan. 16, 2020)	4	Patent Owner	Public

✓	Exhibit # ↓	Filing date	Document name	Pages	Filing party	Availability
✓	2480	01/17/2024	EX2480-IQVIA, "About us," https://www.igvia.com/about-us	5	Patent Owner	Public
✓	2479	01/17/2024	EX2479-Nordrum, A., "11 Blockbuster 'Drugs to Watch' in 2015," Int'l Bus. Times, http://www.ibtimes.com/11-blockbuster-drugs-watch-2015-1857100 (Mar. 24, 2015)	2	Patent Owner	Public
✓	2478	01/17/2024	EX2478-Chen, J., "Blockbuster Drug: What it is, How it works," Investopedia, https://www.investopedia.com/terms/b/blockbuster-drug.asp, last updated Sept. 6, 2022	7	Patent Owner	Public
✓	2477	01/17/2024	EX2477-U.S. Food & Drug Administration, Drugs@FDA, Brenzavvy	2	Patent Owner	Public
✓	2476	01/17/2024	EX2476-Brenzavvy® Prescribing Information (rev. Jan. 2023)	25	Patent Owner	Public
✓	2475	01/17/2024	EX2475-Mounjaro Prescribing Information (rev. July 2023)	47	Patent Owner	Public
✓	2474	01/17/2024	EX2474-U.S. Food & Drug Administration, Drugs@FDA, Mounjaro	3	Patent Owner	Public
✓	2473	01/17/2024	EX2473-U.S. Food & Drug Administration, Drugs@FDA, Trijardy XR	3	Patent Owner	Public
✓	2472	01/17/2024	EX2472-Trijardy® XR Prescribing Information (rev. Jan. 2020)	46	Patent Owner	Public
✓	2471	01/17/2024	EX2471-U.S. Food & Drug Administration, Drugs@FDA, Rybelsus	3	Patent Owner	Public
✓	2470	01/17/2024	EX2470-Rybelsus Prescribing Information (rev. Jan. 2020)	24	Patent Owner	Public
✓	2469	01/17/2024	EX2469-U.S. Food & Drug Administration, Drugs@FDA, Stegluromet	3	Patent Owner	Public
✓	2468	01/17/2024	EX2468-Stegluromet Prescribing Information (rev. Dec. 2017)	36	Patent Owner	Public
✓	2467	01/17/2024	EX2467-U.S. Food & Drug Administration, Drugs@FDA, Steglujan	3	Patent Owner	Public
✓	2466	01/17/2024	EX2466-Steglujan Prescribing Information (rev. Feb. 2018)	36	Patent Owner	Public
✓	2465	01/17/2024	EX2465-U.S. Food & Drug Administration, Drugs@FDA, Steglatro	4	Patent Owner	Public
✓	2464	01/17/2024	EX2464-Steglatro Prescribing Information (rev. Dec. 2017)	27	Patent Owner	Public
✓	2463	01/17/2024	EX2463-U.S. Food & Drug Administration, Drugs@FDA, Ozempic	3	Patent Owner	Public
✓	2462	01/17/2024	EX2462-U.S. Food & Drug Administration, Drugs@FDA, Qtern	3	Patent Owner	Public
✓	2461	01/17/2024	EX2461-Qtern Prescribing Information (rev. Feb. 2017)	42	Patent Owner	Public
✓	2460	01/17/2024	EX2460-U.S. Food & Drug Administration, Drugs@FDA, Xultophy 100/3.6	4	Patent Owner	Public
✓	2459	01/17/2024	EX2459-Xultophy 100/3.6 Prescribing Information (rev. Nov. 2016)	48	Patent Owner	Public
✓	2458	01/17/2024	EX2458-U.S. Food & Drug Administration, Drugs@FDA, Soliqua 100/33	3	Patent Owner	Public
✓	2457	01/17/2024	EX2457-Soliqua 100/33 Prescribing Information (rev. Aug. 2017)	39	Patent Owner	Public
✓	2456	01/17/2024	EX2456-U.S. Food & Drug Administration, Drugs@FDA, Adlyxin	2	Patent Owner	Public
✓	2455	01/17/2024	EX2455-Adlyxin Prescribing Information (rev. July 2016)	72	Patent Owner	Public
✓	2454	01/17/2024	EX2454-U.S. Food & Drug Administration, Drugs@FDA, Synjardy XR	3	Patent Owner	Public
✓	2453	01/17/2024	EX2453-U.S. Food & Drug Administration, Drugs@FDA, Synjardy	6	Patent Owner	Public
✓	2452	01/17/2024	EX2452-Synjardy Prescribing Information (rev. Dec. 2017)	42	Patent Owner	Public

✓	Exhibit # ↓	Filing date	Document name	Pages	Filing party	Availability
✓	2451	01/17/2024	EX2451-U.S. Food & Drug Administration, Drugs@FDA, Glyxambi	4	Patent Owner	Public
✓	2450	01/17/2024	EX2450-Glyxambi Prescribing Information (rev. Dec. 2017)	34	Patent Owner	Public
✓	2449	01/17/2024	EX2449-U.S. Food & Drug Administration, Drugs@FDA, Xigduo® XR	4	Patent Owner	Public
✓	2448	01/17/2024	EX2448-Xigduo® XR Prescribing Information (rev. July 2017)	43	Patent Owner	Public
✓	2447	01/17/2024	EX2447-U.S. Food & Drug Administration, Drugs@FDA, Trulicity®	4	Patent Owner	Public
✓	2446	01/17/2024	EX2446-Trulicity® Prescribing Information (rev. June 2018)	52	Patent Owner	Public
✓	2445	01/17/2024	EX2445-Trulicity® Prescribing Information (rev. Aug. 2017)	51	Patent Owner	Public
✓	2444	01/17/2024	EX2444-U.S. Food & Drug Administration, Drugs@FDA, Invokamet® XR	3	Patent Owner	Public
✓	2443	01/17/2024	EX2443-U.S. Food & Drug Administration, Drugs@FDA, Invokamet®	4	Patent Owner	Public
✓	2442	01/17/2024	EX2442-Invokamet® Prescribing Information (rev. Aug. 2017)	56	Patent Owner	Public
✓	2441	01/17/2024	EX2441-Jardiance® Prescribing Information (rev. Dec. 2016)	34	Patent Owner	Public
✓	2440	01/17/2024	EX2440-U.S. Food & Drug Administration, Drugs@FDA, Jardiance®	6	Patent Owner	Public
✓	2439	01/17/2024	EX2439-Jardiance® Prescribing Information (rev. Dec. 2017)	35	Patent Owner	Public
✓	2438	01/17/2024	EX2438-Hoerman, J., "Tanzeum (albiglutide) Discontinued After FDA Warns of Risk of Anaphylaxis Reaction," https://trulaw.com/fda/tanzeum-albiglutide-anaphylaxis-reaction (Nov. 21, 2017)	4	Patent Owner	Public
✓	2437	01/17/2024	EX2437-U.S. Food & Drug Administration, Drugs@FDA, Tanzeum®	3	Patent Owner	Public
✓	2436	01/17/2024	EX2436-Tanzeum® Prescribing Information (rev. Dec. 2017)	56	Patent Owner	Public
✓	2435	01/17/2024	EX2435-U.S. Food & Drug Administration, Drugs@FDA, Farxiga®	5	Patent Owner	Public
✓	2434	01/17/2024	EX2434-Farxiga® Prescribing Information (rev. Oct. 2017)	31	Patent Owner	Public
✓	2433	01/17/2024	EX2433-U.S. Food & Drug Administration, Drugs@FDA, Invokana®	4	Patent Owner	Public
✓	2432	01/17/2024	EX2432-Invokana® Prescribing Information (rev. July 2017)	48	Patent Owner	Public
✓	2431	01/17/2024	EX2431-U.S. Food & Drug Administration, Drugs@FDA, Oseni®	3	Patent Owner	Public
✓	2430	01/17/2024	EX2430-Oseni® Prescribing Information (rev. Dec. 2017)	45	Patent Owner	Public
✓	2429	01/17/2024	EX2429-U.S. Food & Drug Administration, Drugs@FDA, Kazano®	3	Patent Owner	Public
✓	2428	01/17/2024	EX2428-Kazano® Prescribing Information (rev. Feb. 2017)	35	Patent Owner	Public
✓	2427	01/17/2024	EX2427-U.S. Food & Drug Administration, Drugs@FDA, Nesina®	3	Patent Owner	Public
✓	2426	01/17/2024	EX2426-Nesina® Prescribing Information (rev. Dec. 2016)	31	Patent Owner	Public
✓	2425	01/17/2024	EX2425-Jentadueto® XR Prescribing Information (rev. Dec. 2016)	23	Patent Owner	Public
✓	2424	01/17/2024	EX2424-U.S. Food & Drug Administration, Drugs@FDA, Jentadueto® XR	3	Patent Owner	Public
✓	2423	01/17/2024	EX2423-U.S. Food & Drug Administration, Drugs@FDA, Jentadueto®	6	Patent Owner	Public

✓	Exhibit # ↓	Filing date	Document name	Pages	Filing party	Availability
✓	2422	01/17/2024	EX2422 - Jentadueto® Prescribing Information (rev. Aug. 2017)	23	Patent Owner	Public
✓	2421	01/17/2024	EX2421 - U.S. Food & Drug Administration, Drugs@FDA, Bydureon® BCISE™	4	Patent Owner	Public
✓	2420	01/17/2024	EX2420 - Bydureon® BCISE™ Prescribing Information (rev. Oct. 2017)	33	Patent Owner	Public
✓	2418	01/17/2024	EX2418 - U.S. Food & Drug Administration, Drugs@FDA, Bydureon®	5	Patent Owner	Public
✓	2417	01/17/2024	EX2417 - AstraZeneca, "AstraZeneca and Bristol-Myers Squibb complete expansion of diabetes alliance through Bristol-Myers Squibb's acquisition of Amylin Pharmaceuticals," https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-and-Bristol-Myers-Squibb-complete-expansion-of-diabetes-alliance-through-Bristol-Myers-Squibbs-acquisition-of-Amylin-Pharmaceuticals-09082012.html (Aug. 9, 2012)	2	Patent Owner	Public
✓	2416	01/17/2024	EX2416 - U.S. Food & Drug Administration, Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, ANDA 208335	1	Patent Owner	Public
✓	2415	01/17/2024	EX2415 - U.S. Food & Drug Administration, Drugs@FDA, Tradjenta®	5	Patent Owner	Public
✓	2414	01/17/2024	EX2414 - U.S. Food & Drug Administration, Drugs@FDA, Tradjenta®	16	Patent Owner	Public
✓	2413	01/17/2024	EX2413 - U.S. Food & Drug Administration, Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, ANDA 206081	2	Patent Owner	Public
✓	2412	01/17/2024	EX2412 - U.S. Food & Drug Administration, Drugs@FDA, Kombiglyze® XR	3	Patent Owner	Public
✓	2411	01/17/2024	EX2411 - Kombiglyze® XR Prescribing Information (rev. Feb. 2017)	50	Patent Owner	Public
✓	2410	01/17/2024	EX2410 - Novo Nordisk, "Dosing and administering Victoza®," https://www.novomedlink.com/diabetes/products/treatments/victoza/dosing-administration.html	11	Patent Owner	Public
✓	2409	01/17/2024	EX2409 - Victoza® Prescribing Information (rev. Aug. 2017)	40	Patent Owner	Public
✓	2408	01/17/2024	EX2408 - U.S. Food & Drug Administration, Drugs@FDA, Victoza®	4	Patent Owner	Public
✓	2407	01/17/2024	EX2407 - Victoza® Prescribing Information (rev. Nov. 2020)	40	Patent Owner	Public
✓	2406	01/17/2024	EX2406 - Aurobindo, "Aurobindo Received FDA Approval for Saxagliptin Tablets, 2.5mg and 5mg," https://www.aurobindousa.com/news/product-news/aurobindo-receives-fda-approval-for-saxagliptin-tablets-2-5mg-and-5mg/ (July 31, 2023)	2	Patent Owner	Public
✓	2405	01/17/2024	EX2405 - U.S. Food & Drug Administration, Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, ANDA 205981	2	Patent Owner	Public
✓	2404	01/17/2024	EX2404 - U.S. Food & Drug Administration, Drugs@FDA, Onglyza®	3	Patent Owner	Public
✓	2403	01/17/2024	EX2403 - Onglyza® Prescribing Information (rev. Feb. 2017)	33	Patent Owner	Public
✓	2402	01/17/2024	EX2402 - U.S. Food & Drug Administration, Drugs@FDA, Janumet® XR	4	Patent Owner	Public
✓	2401	01/17/2024	EX2401 - U.S. Food & Drug Administration, Drugs@FDA, Janumet®	5	Patent Owner	Public
✓	2400	01/17/2024	EX2400 - Janumet® Prescribing Information (rev. Feb. 2018)	35	Patent Owner	Public
✓	2399	01/17/2024	EX2399 - U.S. Food & Drug Administration, Drugs@FDA, Januvia®	5	Patent Owner	Public
✓	2398	01/17/2024	EX2398 - Januvia® Prescribing Information (rev. Feb. 2018)	26	Patent Owner	Public
✓	2397	01/17/2024	EX2397 - U.S. Food & Drug Administration, FDA List of Authorized Generics, https://www.fda.gov/media/77725/download, last updated Jan. 4, 2024	97	Patent Owner	Public
✓	2396	01/17/2024	EX2396 - U.S. Food & Drug Administration, Drugs@FDA, Byetta®	5	Patent Owner	Public
✓	2395	01/17/2024	EX2395 - Byetta® Prescribing Information (rev. Feb. 2015)	39	Patent Owner	Public

✓	Exhibit # ↓	Filing date	Document name	Pages	Filing party	Availability
✓	2394	01/17/2024	EX2394 - Mansfield, C., et al., Patient Preferences for Attributes of Type 2 Diabetes Mellitus Medications in Germany and Spain: An Online Discrete-Choice Experiment Survey, Diabetes Ther., 2017 Dec.; 8(6):1365-1378	14	Patent Owner	Public
✓	2393	01/17/2024	EX2393 - DiBonaventura, M.d., et al., Multinational Internet-based survey of patient preference for newer oral or injectable Type 2 diabetes medication, Patient Prefer. Adherence, 2010; 4:397-406	10	Patent Owner	Public
✓	2392	01/17/2024	EX2392 - Baryakova, T.H., et al., Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems, Nature Reviews Drug Discovery, 2023; 22:387-409	23	Patent Owner	Public
✓	2391	01/17/2024	EX2391 - Brown, M.T. and Bussell, J.K., Medication Adherence: WHO Cares?, Mayo Clin. Proc., 2011 Apr.; 86(4): 304-314	11	Patent Owner	Public
✓	2390	01/17/2024	EX2390 - Usherwood, T., Encouraging adherence to long-term medication, Aust. Prescr., 2017 Aug.; 40(4):147-150	4	Patent Owner	Public
✓	2389	01/17/2024	EX2389 - Ho, P.M., Bryson, C.L., and Rumsfeld, J.S., Medication Adherence, Circulation, 2009; 119(23):3028-3035	8	Patent Owner	Public
✓	2388	01/17/2024	EX2388 - Cramer, J.A., Medication compliance and persistence: terminology and definitions, Value Health 2008 Jan-Feb; 11(1):44-47	4	Patent Owner	Public
✓	2387	01/17/2024	EX2387 - American Heart Association, "Cardiovascular Disease and Diabetes," https://www.heart.org/en/health-topics/diabetes/diabetes-complications-and-risks/cardiovascular-disease--diabetes, last reviewed May 4, 2021	5	Patent Owner	Public
✓	2386	01/17/2024	EX2386 - National Institute for Health and Care Research, "Losing weight following type 2 diabetes diagnosis boosts chance of remission," https://evidence.nihr.ac.uk/not-articletype/losing-weight-following-type-2-diabetes-diagnosis-boosts-chance-of-remission (Nov. 21, 2019)	4	Patent Owner	Public
✓	2385	01/17/2024	EX2385 - Wilding, J.P.H., The importance of weight management in type 2 diabetes mellitus, Int. J. Clin. Pract., 2014 Jun; 68(6):682-691	10	Patent Owner	Public
✓	2384	01/17/2024	EX2384 - Clamp, L.D., et al., Enhanced insulin sensitivity in successful, long-term weight loss maintainers compared with matched controls with no weight loss history, Nutrition & Diabetes, 2017; 7:e282	8	Patent Owner	Public
✓	2383	01/17/2024	EX2383 - Bishop, S., "Losing Weight Can Have Big Impact on Those With Diabetes," https://newsnetwork.mayoclinic.org/discussion/losing-weight-can-have-big-impact-on-those-with-diabetes (Dec. 14, 2012)	3	Patent Owner	Public
✓	2382	01/17/2024	EX2382 - Boyes, K.S., et al., Physician Perceptions of Dose Escalation for Type 2 Diabetes Medications in the United States, Diabetes Ther., 2023 Nov., https://doi.org/10.1007/s13300-023-01499-x	13	Patent Owner	Public
✓	2381	01/17/2024	EX2381 - Valentine, V., Goldman, J. and Shubrook, J.H., Rationale for Initiation and Titration of the Basal Insulin/GLP-1RA Fixed-Ratio Combination Products, IDegLira and IGLarLixi, for the Management of Type 2 Diabetes, Diabetes Ther., 2017 July; 8:739-752	14	Patent Owner	Public
✓	2380	01/17/2024	EX2380 - Mayo Clinic, "A1C test," https://www.mayoclinic.org/tests-procedures/a1c-test/about/pac-20384643, last updated Dec. 1, 2022	2	Patent Owner	Public
✓	2379	01/17/2024	EX2379 - Novo Nordisk, "Managing your diabetes," https://www.mynovoinsulin.com/diabetes-education/managing-diabetes.html, last updated Dec. 2022	6	Patent Owner	Public
✓	2378	01/17/2024	EX2378 - American Diabetes Association, "Life with Diabetes: Get the Right Care for You," http://www.diabetes.org/living-with-diabetes/treatment-and-care	6	Patent Owner	Public
✓	2377	01/17/2024	EX2377 - Janssen Pharmaceuticals, Inc., "U.S. FDA Approves INVOKANA™ (Canagliflozin) for the Treatment of Adults with Type 2 Diabetes," https://www.prnewswire.com/news-releases/us-fda-approves-invokana-canagliflozin-for-the-treatment-of-adults-with-type-2-diabetes-200638361.html (Mar. 29, 2013)	13	Patent Owner	Public
✓	2376	01/17/2024	EX2376 - Kalra, S., Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology, Diabetes Ther., 2014 Dec.; 5(2):355-366	12	Patent Owner	Public
✓	2375	01/17/2024	EX2375 - U.S. Food & Drug Administration, Approval Letter for Januvia® (Oct. 16, 2006)	5	Patent Owner	Public
✓	2374	01/17/2024	EX2374 - Tran, K.L., et al., Overview of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Patients with Type 2 Diabetes, Am. Health Drug Benefits 2017 Jun; 10(4):178-188	11	Patent Owner	Public
✓	2373	01/17/2024	EX2373 - Cleveland Clinic, "GLP-1 Agonists," https://my.clevelandclinic.org/health/treatments/13901-gl-p-1-agonists, last reviewed July 3, 2023	13	Patent Owner	Public

✓	Exhibit # ↓	Filing date	Document name	Pages	Filing party	Availability
✓	2372	01/17/2024	EX2372 - Eggleston, J.S. and Jialal, J., Thiazolidinediones, StatPearls [Internet], available at https://www.ncbi.nlm.nih.gov/books/NBK551656/, last updated Feb. 20, 2023	7	Patent Owner	Public
✓	2371	01/17/2024	EX2371 - U.S. Food & Drug Administration, Drugs@FDA, Prandin®	4	Patent Owner	Public
✓	2370	01/17/2024	EX2370 - White, Jr., J.R., A Brief History of the Development of Diabetes Medications, Diabetes Spectr. 2014;27(2):82-86	5	Patent Owner	Public
✓	2369	01/17/2024	EX2369 - Tomkin, G.H., Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitors, World J. Diabetes. 2014 Oct. 15; 5(5):636-650	5	Patent Owner	Public
✓	2368	01/17/2024	EX2368 - Tomkin, G.H., Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitors, World J. Diabetes. 2014 Oct. 15; 5(5):636-650	16	Patent Owner	Public
✓	2367	01/17/2024	EX2367 - Sirtori, C.R. and Pasik, C., Re-evaluation of a biguanide, metformin: mechanism of action and tolerability, Pharmacol. Res. 1994 Oct-Nov; 30(3):187-228	42	Patent Owner	Public
✓	2366	01/17/2024	EX2366 - Cleveland Clinic, "Biguanides," https://my.clevelandclinic.org/health/treatments/25004-biguanides, last reviewed May 22, 2023	10	Patent Owner	Public
✓	2366	01/17/2024	EX2366 - Cleveland Clinic, "Biguanides," https://my.clevelandclinic.org/health/treatments/25004-biguanides, last reviewed May 22, 2023	9	Patent Owner	Public
✓	2365	01/17/2024	EX2365 - U.S. Food & Drug Administration, Drugs@FDA, Amaryl®	5	Patent Owner	Public
✓	2364	01/17/2024	EX2364 - U.S. Food & Drug Administration, Drugs@FDA, Glucotrol®	3	Patent Owner	Public
✓	2363	01/17/2024	EX2363 - U.S. Food & Drug Administration, Drugs@FDA, Micronase®	4	Patent Owner	Public
✓	2362	01/17/2024	EX2362 - U.S. Food & Drug Administration, Drugs@FDA, Diabeta®	5	Patent Owner	Public
✓	2361	01/17/2024	EX2361 - National Institute of Diabetes and Digestive and Kidney Diseases, "Low Blood Glucose (Hypoglycemia)," https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/low-blood-glucose-hypoglycemia, last reviewed July 2021	10	Patent Owner	Public
✓	2360	01/17/2024	EX2360 - Quianzon, C.C.L. and Cheick, J.E., History of current non-insulin medications for diabetes mellitus, J. Community Hosp. Intern. Med. Perspect. 2012 Oct. 15; 2(3). Doi: 10.3402/jchimp.v2i3.19081	4	Patent Owner	Public
✓	2359	01/17/2024	EX2359 - Moses, R.G., Combination Therapy for Patients with Type 2 Diabetes: Repaglinide in Combination with Metformin, Overview of Oral Antidiabetic Medications, https://www.medscape.com/viewarticle/722513_3	15	Patent Owner	Public
✓	2358	01/17/2024	EX2358 - Mayo Clinic, "Type 2 diabetes - Diagnosis & Treatment," https://www.mayoclinic.org/diseases-conditions/type-2-diabetes/diagnosis-treatment/drc-20351199, last updated March 14, 2023	7	Patent Owner	Public
✓	2357	01/17/2024	EX2357 - National Institute of Diabetes and Digestive Kidney Diseases, "Type 2 Diabetes," https://www.niddk.nih.gov/health-information/diabetes/overview/what-is-diabetes/type-2-diabetes, last reviewed May 2017	6	Patent Owner	Public
✓	2356	01/17/2024	EX2356 - Centers for Disease Control and Prevention, National Diabetes Statistics Report 2020: Estimates of Diabetes and Its Burden in the United States (2020)	32	Patent Owner	Public
✓	2355	01/17/2024	EX2355 - National Institute of Diabetes and Digestive Kidney Diseases, "Dictionary Definition: insulin," https://www.niddk.nih.gov/Dictionary/I/insulin	1	Patent Owner	Public
✓	2354	01/17/2024	EX2354 - Centers for Disease Control and Prevention, "Gestational Diabetes," https://www.cdc.gov/diabetes/basics/gestational.html, last reviewed Dec. 30, 2022	3	Patent Owner	Public
✓	2353	01/17/2024	EX2353 - Mayo Clinic, "Hyperglycemia in diabetes - Symptoms & causes," https://www.mayoclinic.org/diseases-conditions/hyperglycemia/symptoms-causes/syc-20373631, last updated Aug. 20, 2022	4	Patent Owner	Public
✓	2352	01/17/2024	EX2352 - Mayo Clinic, "Diabetes - Symptoms & causes," https://www.mayoclinic.org/diseases-conditions/diabetes/symptoms-causes/syc-20371444, last updated Sept. 15, 2023	3	Patent Owner	Public
✓	2351	01/17/2024	EX2351 - National Institute of Diabetes and Digestive Kidney Diseases, "What is Diabetes," https://www.niddk.nih.gov/health-information/diabetes/overview/what-is-diabetes, last reviewed April 2023	4	Patent Owner	Public
✓	2334	01/17/2024	EX2334 - January 17, 2018 Pre-POA opening presentation (produced as NN-OZEM-004751127) [UNDER SEAL]	145	Patent Owner	Parties and Board
✓	2333	01/17/2024	EX2333 - August 11, 2020 Integrated Insights Ecosystem, Wave 2 Quarterly Report presentation (produced as NN-OZEM-004741982) [UNDER SEAL]	89	Patent Owner	Parties and Board

✓	Exhibit # ↓	Filing date	Document name	Pages	Filing party	Availability
✓	2332	01/17/2024	EX2332 - May 2017 GLP-1 Franchise Patient Segmentation Results & Recommendations presentation (produced as NN-OZEM-004731509). [UNDER SEAL]	40	Patent Owner	Parties and Board
✓	2331	01/17/2024	EX2331 - May 6, 2020 Integrated Insights Ecosystem Wave 1 Quarterly Report presentation (produced as NN-OZEM-004724606). [UNDER SEAL]	73	Patent Owner	Parties and Board
✓	2330	01/17/2024	EX2330 - November 11, 2020 Integrated Insights Ecosystem Wave 3 Quarterly Report presentation (produced as NN-OZEM-004723593). [UNDER SEAL]	66	Patent Owner	Parties and Board
✓	2329	01/17/2024	EX2329 - January 4, 2021 CV Region New Year Kick-Off Meeting presentation (produced as NN-OZEM-004723449). [UNDER SEAL]	71	Patent Owner	Parties and Board
✓	2328	01/17/2024	EX2328 - August 8, 2021 specifications for detailing material (produced as NN-OZEM-004717717). [UNDER SEAL]	18	Patent Owner	Parties and Board
✓	2327	01/17/2024	EX2327 - February 17, 2021 Integrated Insights Ecosystem Wave 4 Quarterly Insights Report presentation (produced as NN-OZEM-004701779). [UNDER SEAL]	63	Patent Owner	Parties and Board
✓	2326	01/17/2024	EX2326 - November 16, 2021 Quarterly Insights Report - Q3' 2021 Diabetes Integrated Insights Ecosystem presentation (produced as NN-OZEM-004691816). [UNDER SEAL]	51	Patent Owner	Parties and Board
✓	2325	01/17/2024	EX2325 - February 23, 2022 Quarterly Insights Report - Q4' 2021 Diabetes Integrated Insights Ecosystem presentation (produced as NN-OZEM-004691302). [UNDER SEAL]	60	Patent Owner	Parties and Board
✓	2324	01/17/2024	EX2324 - May 2017 Brand Strategy 2018 GLP-1 Franchise presentation (produced as NN-OZEM-004690786). [UNDER SEAL]	17	Patent Owner	Parties and Board
✓	2323	01/17/2024	EX2323 - February 26, 2019 Ozempic US Launch Tracker presentation (produced as NN-OZEM-004688496). [UNDER SEAL]	12	Patent Owner	Parties and Board
✓	2322	01/17/2024	EX2322 - February 17, 2021 Integrated Insights Ecosystem Wave 4 Quarterly Insights Report presentation (produced as NN-OZEM-004687270). [UNDER SEAL]	63	Patent Owner	Parties and Board
✓	2321	01/17/2024	EX2321 - September 10, 2018 GLP-1ATU 3Q18 presentation (produced as NN-OZEM-004684467). [UNDER SEAL]	63	Patent Owner	Parties and Board
✓	2320	01/17/2024	EX2320 - September 12, 2018 GLP-1 ATU 3Q18 West Area Analysis presentation (produced as NN-OZEM-004684107). [UNDER SEAL]	26	Patent Owner	Parties and Board
✓	2318	01/17/2024	EX2318 - March 28, 2018 GfK Replinsight spreadsheet (produced as NN-OZEM-004681464). [UNDER SEAL]	64	Patent Owner	Parties and Board
✓	2317	01/17/2024	EX2317 - June 2, 2021 Integrated Insights Ecosystem 2021 Q1 Quarterly Insights Report presentation (produced as NN-OZEM-004680250). [UNDER SEAL]	57	Patent Owner	Parties and Board
✓	2316	01/17/2024	EX2316 - May 6, 202 Integrated Insights Ecosystem Wave 1 Quarterly Insights Report presentation (produced as NN-OZEM-004679316). [UNDER SEAL]	73	Patent Owner	Parties and Board
✓	2315	01/17/2024	EX2315 - November 5, 2019 Ozempic US Launch Tracker presentation (produced as NN-OZEM-004677154). [UNDER SEAL]	10	Patent Owner	Parties and Board
✓	2314	01/17/2024	EX2314 - May 16, 2017 Semaglutide Ad Board Market Overview presentation (produced as NN-OZEM-004656390). [UNDER SEAL]	44	Patent Owner	Parties and Board
✓	2313	01/17/2024	EX2313 - November 5, 2019 Market Overview/GLP-1 Strategy presentation (produced as NN-OZEM-004300946). [UNDER SEAL]	67	Patent Owner	Parties and Board
✓	2312	01/17/2024	EX2312 - September 5, 2018 Novo Nordisk/Non-Insulin Market Weekly Performance Report spreadsheet (produced as NN-OZEM-004063922). [UNDER SEAL]	19	Patent Owner	Parties and Board
✓	2311	01/17/2024	EX2311 - June 13, 2017 Market Access - Track 6 presentation (produced as NN-OZEM-004055726). [UNDER SEAL]	18	Patent Owner	Parties and Board
✓	2310	01/17/2024	EX2310 - September 22, 2018 SC Semaglutide QW, US RWE Plan presentation (produced as NN-OZEM-003971783). [UNDER SEAL]	12	Patent Owner	Parties and Board
✓	2309	01/17/2024	EX2309 - September 18, 2018 Semaglutide NNI Evidence Generation Plan - 2018-2021/25 presentation (produced as NN-OZEM-003793796). [UNDER SEAL]	32	Patent Owner	Parties and Board
✓	2308	01/17/2024	EX2308 - July 6, 2018 Product Development Plan Ozempic® NN9535 (produced as NN-OZEM-003735283). [UNDER SEAL]	50	Patent Owner	Parties and Board
✓	2307	01/17/2024	EX2307 - January 12, 2018 Ozempic® Brand Presentation (produced as NN-OZEM-003732120). [UNDER SEAL]	100	Patent Owner	Parties and Board
✓	2306	01/17/2024	EX2306 - January 30, 2018 Brand Strategy presentation (produced as NN-OZEM-003732069). [UNDER SEAL]	84	Patent Owner	Parties and Board
✓	2305	01/17/2024	EX2305 - September 13, 2021 internal specifications for the Ozempic® website with savings card details (produced as NN-OZEM-003242796). [UNDER SEAL]	2	Patent Owner	Parties and Board
✓	2304	01/17/2024	EX2304	40	Patent Owner	Parties and Board

✓	Exhibit # ↓	Filing date	Document name	Pages	Filing party	Availability
✓	2303	01/17/2024	EX2303	3	Patent Owner	Parties and Board
✓	2302	01/17/2024	EX2302 - February 27, 2020 Specifications for 2020 Ozempic® People Cover Wrap (produced as NN-OZEM-003176580) [UNDER SEAL]	5	Patent Owner	Parties and Board
✓	2301	01/17/2024	EX2301 - IQVIA Data [UNDER SEAL]	254	Patent Owner	Parties and Board
✓	2300	01/17/2024	EX2300 - Declaration of Christopher A. Vellturo, Ph.D. [UNDER SEAL AND REDACTED COPIES]	170	Patent Owner	Parties and Board
✓	2300	01/17/2024	EX2300 - Declaration of Christopher A Vellturo, Ph.D. [REDACTED]	170	Patent Owner	Public
✓	2113	01/17/2024	EX2113 - Victoza® FDA Approval Letter (Jan. 25, 2010)	11	Patent Owner	Public
✓	2112	01/17/2024	EX2112 - Terry, T., et al., Does aggressive glycemic control benefit macrovascular and microvascular disease in type 2 diabetes? Insights from ACCORD, ADVANCE, and VADT. Curr. Cardiol. Rep., 14(1):79-88 (2012)	10	Patent Owner	Public
✓	2111	01/17/2024	EX2111 - Verma, S., et al., Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials. Diabetes Obes. Metab., 22:2487-2492 (2020)	6	Patent Owner	Public
✓	2110	01/17/2024	EXPUNGED	8	Patent Owner	EXPUNGED-Public
✓	2110	04/25/2024	EX2110 - Verges, B. and Charbonnel, B., After the LEADER trial and SUSTAIN-6, how do we explain the cardiovascular benefits of some GLP-1 receptor agonists? Diabetes Metab. 43: 2s3-2s12 (2017)	10	Patent Owner	Public
✓	2109	01/17/2024	EX2109 - Sattar, N., et al., Novel Diabetes Drugs and the Cardiovascular Specialist. J. Am. Coll. Cardiol., 69: 2646-2656 (2017)	11	Patent Owner	Public
✓	2108	01/17/2024	EX2108 - Reiter-Brennan, C., Comprehensive Care Models for Cardiometabolic Disease. Curr. Cardiol. Rep., 23(3):22 (2021)	11	Patent Owner	Public
✓	2107	01/17/2024	EX2107 - Ozempic FDA Approval Letter for sNDA (March 28, 2022)	5	Patent Owner	Public
✓	2106	01/17/2024	EX2106 - Ozempic FDA Approval Letter (Dec. 15, 2017)	8	Patent Owner	Public
✓	2105	01/17/2024	EX2105 - Nauck, M.A., et al., Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. Circulation, 186: 849-870 (2017)	22	Patent Owner	Public
✓	2104	01/17/2024	EX2104 - Maskery, M.P., et al., Glucagon-like peptide-1 receptor agonists as neuroprotective agents for ischemic stroke: a systematic scoping review. J. Cereb. Blood Flow Metab., 41:14-30 (2020)	17	Patent Owner	Public
✓	2103	01/17/2024	EX2103 - Marx, N., et al., GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients with Type 2 Diabetes. Circulation, 146:1882-1894 (2022)	13	Patent Owner	Public
✓	2102	01/17/2024	EX2102 - Marso, S.P., et al., Supplementary Appendix to Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N. Engl. J. Med., 375:1834-1844 (2016)	109	Patent Owner	Public
✓	2101	01/17/2024	EX2101 - Marso, S.P., et al., Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N. Engl. J. Med., 375:1834-1844 (2016)	11	Patent Owner	Public
✓	2100	01/17/2024	EX2100 - Leiter, L.A., et al., Cardiovascular risk reduction with once weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial. Cardiovasc. Diabetol., 18:73 (2019)	12	Patent Owner	Public
✓	2099	01/17/2024	EX2099 - Kleindorfer, D.O., et al., Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack. Stroke, 52:e364-e467 (2021)	104	Patent Owner	Public
✓	2098	01/17/2024	EX2098 - Jha, K.K., et al., Transitioning to GLP-1 RAs and SGLT2 Inhibitors as the First Choice for Managing Cardiometabolic Risk in Type 2 Diabetes. Curr. Atheroscler. Rep., 24:925-937 (2022)	13	Patent Owner	Public
✓	2097	01/17/2024	EX2097 - Garcia-Casares, N., et al., Effects of GLP-1 receptor agonists on neurological complications of diabetes. Rev. Endocr. Metab. Disord., 24:655-672 (2023)	18	Patent Owner	Public
✓	2095	01/17/2024	EX2095 - Evans, L.M., et al., A population-adjusted indirect comparison of cardiovascular benefits of once-weekly subcutaneous semaglutide and dulaglutide in the treatment of patients with type 2 diabetes, with or without established cardiovascular disease. Endocrinol. Diab. Metab. 2021;4:e00259 (2021)	10	Patent Owner	Public

✓	Exhibit # ↓	Filing date	Document name	Pages	Filing party	Availability
✓	2094	01/17/2024	EX2094 -Eckel, R.H. and Blaha, M.J., Cardiometabolic Medicine: A Call for a New Subspecialty Training Track in Internal Medicine, Am. J. Med., 132(7):788-790 (2019).	3	Patent Owner	Public
✓	2093	01/17/2024	EX2093 -Davies, M.J. et al., Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes, Cardiovasc. Diabetol., 21:144 (2022)	20	Patent Owner	Public
✓	2092	01/17/2024	EX2092 -Das, S.R., et al., Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients with Type 2 Diabetes, J. Am. Coll. Cardiol., 76: 1117-1145 (2020).	48	Patent Owner	Public
✓	2091	01/17/2024	EX2091 -Das, S.R., et al., ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease, J. Am. Coll. Cardiol., 72: 3200-3223 (2018)	46	Patent Owner	Public
✓	2090	01/17/2024	EX2090 -Cosentino, F. et al., ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD, Eur. Heart J., 41:255-323 (2019).	70	Patent Owner	Public
✓	2089	01/17/2024	EX2089 -American Society for Preventive Cardiology, "Cardiometabolic Fellowship," https://www.aspconline.org/professional-development/cardiometabolic-fellowship (last visited Jan. 16, 2024).	3	Patent Owner	Public
✓	2088	01/17/2024	EX2088 -American College of Cardiology, "Clinical Topics: Diabetes and Cardiometabolic Disease," https://www.acc.org/Clinical-Topics/Diabetes-and-Cardiometabolic-Disease (last visited Jan. 16, 2024).	4	Patent Owner	Public
✓	2087	01/17/2024	EX2087 -ADA Standards of Medical Care, Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes, Diabetes Care 45(Suppl. 1):S144-S175 (2022).	32	Patent Owner	Public
✓	2086	01/17/2024	EX2086 -Abdul-Ghani, M., et al., Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?, Diabetes Care, 40:813-820 (2017).	8	Patent Owner	Public
✓	2085	01/17/2024	EX2085 -A. Ahmann et al., "Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects with Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial," Diabetes Care 2018;41:258-266	9	Patent Owner	Public
✓	2084	01/17/2024	EX2084 -R. Pratley et al., "Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomized, open-label, phase 3b trial," Lancet Diabetes Endocrinol 6:275-86 (2018)	12	Patent Owner	Public
✓	2083	01/17/2024	EX2083 -V. Aroda et al., "Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naïve patients with type 2 diabetes (SUSTAIN 4): a randomized, open-label, parallel-group, multicentre, multinational, phase 3a trial," Lancet Diabetes Endocrinol 5:355-66 (2017).	12	Patent Owner	Public
✓	2082	01/17/2024	EX2082 -M.S. Capehorn et al., "Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10), Diabetes & Metabolism 46 100-109 (2020).	10	Patent Owner	Public
✓	2081	01/17/2024	EX2081 -Dani Blum, "What's Next for Ozempic," New York Times, December 20, 2023	12	Patent Owner	Public
✓	2080	01/17/2024	EX2080 -Dhruv Khullar, "The Year of Ozempic," New Yorker, December 14, 2023, available at https://www.newyorker.com/culture/2023-in-review/the-year-of-ozempic (last visited January 13, 2024).	12	Patent Owner	Public
✓	2079	01/17/2024	EX2079 -United States Patent and Trademark Office, Consolidated Trial Practice Guide, Appendix B Default Protective Order (November 2019).	22	Patent Owner	Public
✓	2078	01/17/2024	EX2078 -Blüher, M. et al., "Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomized clinical trial," Diabetologia (2023), available at https://link.springer.com/content/pdf/10.1007/s00125-023-06053-9.pdf	13	Patent Owner	Public
✓	2077	01/17/2024	EX2077 -Mueller, C., "University of South Carolina Upstate, CHEM U109 Chemistry of Living Things," 9.1:Solutions, available at https://chem.libretexts.org/Courses/University_of_South_Carolina_Upstate/USC_Upstate%3A_CHEM_U109_-_Chemistry_of_Living_Things_(Mueller)/09%3A_Solutions/9.1%3A_Solutions (last visited January 16, 2024).	6	Patent Owner	Public
✓	2076	01/17/2024	EX2076 -Ozempic® Prescribing Information (March 2022).	70	Patent Owner	Public
✓	2075	01/17/2024	EX2075 -Madsbad, S. et al., "Improved Glycemic Control With No Weight Increase in Patients With Type 2 Diabetes After Once-Daily Treatment With the Long-Acting Glucagon-Like Peptide 1 Analog Liraglutide (NN2211)," Diabetes Care, Vol.27, Issue 6, 1335-1342 (June 2004).	8	Patent Owner	Public

✓	Exhibit # ↓	Filing date	Document name	Pages	Filing party	Availability
✓	2074	01/17/2024	EX2074 - Ozempic® Prescribing Information (Australian Product Information) (December 2020) available at https://www.novonordisk.com.au/content/dam/nncorp/au/en/pdfs/Ozempic%20Product%20Information%20Nov%202020.pdf (last visited January 12, 2024)	12	Patent Owner	Public
✓	2073	01/17/2024	EX2073 - Novo Nordisk's Ozempic 0.5 mg solution for injection in pre-filled pen, available at https://www.medicines.org.uk/emc/product/9750/smpc#gref (last visited January 12, 2024)	19	Patent Owner	Public
✓	2072	01/17/2024	EX2072 - Ozempic® Prescribing Information (December 2017)	44	Patent Owner	Public
✓	2071	01/17/2024	EX2071 - Claim Construction Order, In re: Ozempic (Semaglutide) Patent Litigation, MDL No. 22-MD-3038, Dkt. No. 148 (D. Del. July 25, 2023)	8	Patent Owner	Public
✓	2070	01/17/2024	EX2070 - NCT03144271, "Dose Escalation of Single Subcutaneous Doses of NNC 0113-0217 to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male Subjects," available at https://clinicaltrials.gov/study/NCT03144271 (last visited December 28, 2023)	11	Patent Owner	Public
✓	2069	01/17/2024	EX2069 - Ozempic® Prescribing Information (September 2023)	53	Patent Owner	Public
✓	2068	01/17/2024	EX2068 - Victoza® Prescribing Information (January 2010)	23	Patent Owner	Public
✓	2067	01/17/2024	EX2067 - Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare, "Report on the Deliberation Results," available at https://www.pmda.go.jp/files/000153180.pdf (December 3, 2009)	119	Patent Owner	Public
✓	2066	01/17/2024	EX2066 - Kim, K., et al., "Differences in Drug Pharmacokinetics Between East Asians and Caucasians and the Role of Genetic Polymorphisms," J Clin Pharmacol, Vol. 44, 1083-1105 (2004)	23	Patent Owner	Public
✓	2065	01/17/2024	EX2065 - Novo Nordisk, "Annual Report 2010" (February 1, 2011)	116	Patent Owner	Public
✓	2064	01/17/2024	EX2064 - Synapse, "Pegylated GLP-1 analogue (LY2428757) - (Eli Lilly & Co.)," available at https://synapse.patsnap.com/drug/482a547adeba4170ab23efa225fb966d (last updated December 27, 2023)	8	Patent Owner	Public
✓	2063	01/17/2024	EX2063 - OPTUMRx, "Tanzeum® (albiglutide) - Drug Discontinuation," available at https://professionals.optumrx.com/content/dam/optum3/professional-optumrx/news/rxnews/drug-recalls-shortages/drugwithdrawal_tanzeum_2017-0801.pdf (2017)	1	Patent Owner	Public
✓	2062	01/17/2024	EX2062 - Rosenstock, J., et al., "Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes," Diabetes Care, Vol. 32, Issue 10, 1880-1886 (October 2009)	7	Patent Owner	Public
✓	2061	01/17/2024	EX2061 - Nordqvist, C., "Experimental Diabetes Drug Taspoglutide Late-Stage Trials Suspended," available at https://www.medicalnewstoday.com/articles/200893#1 (September 13, 2010)	3	Patent Owner	Public
✓	2060	01/17/2024	EX2060 - Rosenstock, J., et al., "The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes," Diabetes Care, Vol. 36, 498-504 (March 2013)	7	Patent Owner	Public
✓	2059	01/17/2024	EX2059 - Declaration of Vanessa Costain	7	Patent Owner	Public
✓	2058	01/17/2024	EX2058 - Declaration of Sayem Osman	94	Patent Owner	Public
✓	2057	01/17/2024	EX2057 - Declaration of Jenna DiCicco	4	Patent Owner	Public
✓	2056	01/17/2024	EX2056 - Declaration of Patrick J. Sinko, Ph.D. (UNDER SEAL AND REDACTED COPIES)	102	Patent Owner	Parties and Board
✓	2056	01/17/2024	EX2056 - EX2056 - Declaration of Patrick Sinko, Ph.D. (REDACTED)	102	Patent Owner	Public
✓	2055	01/17/2024	EX2055 - Declaration of Michael J. Blaha, M.D.	98	Patent Owner	Public
✓	2054	01/17/2024	EX2054 - Declaration of Robin S. Goland, M.D.	61	Patent Owner	Public
✓	2053	01/17/2024	EX2053 - Declaration of Smita Agarwal	2	Patent Owner	Public

✓	Exhibit # ↓	Filing date	Document name	Pages	Filing party	Availability
✓	2052	01/17/2024	EX2052 - Declaration of Chloe Jiang	20	Patent Owner	Public
✓	2051	01/17/2024	EX2051 - Declaration of Anne Flint [UNDER SEAL AND REDACTED COPIES]	11	Patent Owner	Parties and Board
✓	2051	01/17/2024	EX2051 - Declaration of Anne Flint, Ph. D. [REDACTED]	11	Patent Owner	Public
✓	2050	01/17/2024	EX2050 - Declaration of Christine B. Jensen, Ph.D. [UNDER SEAL AND REDACTED COPIES]	26	Patent Owner	Parties and Board
✓	2050	01/17/2024	EX2050 - Declaration of Christine B. Jensen, M.D., Ph.D. [REDACTED]	26	Patent Owner	Public
✓	2049	01/17/2024	EX2049 - Declaration of Devraj Chakravarty	3	Patent Owner	Public
✓	2048	01/17/2024	EX2048 - Drug Product Semaglutide B, 1.34 mg/ml, Description and Composition of the Drug Product [UNDER SEAL]	3	Patent Owner	Parties and Board
✓	2047	01/17/2024	EX2047 - May 28, 2010 DPComm Clipping, (produced as NN-OZEM-004338872) [UNDER SEAL]	2	Patent Owner	Parties and Board
✓	2046	01/17/2024	EX2046 - May 20, 2010 DPComm Summary Sheet (produced as NN-OZEM-004338873) [UNDER SEAL]	4	Patent Owner	Parties and Board
✓	2041	01/17/2024	EX2041 - November 26, 2010 email from Anne Flint to Christine Jensen et al (produced as NN-OZEM-004434628) [UNDER SEAL]	3	Patent Owner	Parties and Board
✓	2040	01/17/2024	EX2040 - November 26, 2010 draft Clinical Trial Protocol for NN9535-3819 (produced as NN-OZEM-004434630) [UNDER SEAL]	87	Patent Owner	Parties and Board
✓	2039	01/17/2024	EX2039 - March 11, 2010 draft Semaglutide Dose selection for phase 3 presentation (produced as NN-OZEM-004442970) [UNDER SEAL]	29	Patent Owner	Parties and Board
✓	2038	01/17/2024	EX2038 - March 11, 2010 email from Anne Flint to Nilas Ohrner copying Christine Jensen (produced as NN-OZEM-004442969) [UNDER SEAL]	2	Patent Owner	Parties and Board
✓	2036	01/17/2024	EX2036 - NN9535-3819 CTR Workflow (produced as NN-OZEM-004437994) [UNDER SEAL]	6	Patent Owner	Parties and Board
✓	2035	01/17/2024	EX2035 - September 18, 2011 email from Lisbeth Vesterg Jacobsen to Christine Jensen (produced as NN-OZEM-004435304) [UNDER SEAL]	2	Patent Owner	Parties and Board
✓	2034	01/17/2024	EX2034 - September 19, 2011 NN9535-3819 Safety Committee Meeting (produced as NN-OZEM-004435305) [UNDER SEAL]	13	Patent Owner	Parties and Board
✓	2033	01/17/2024	EX2033 - September 24, 2012 NN9535-3819 Clinical Trial Report (produced as NN-OZEM-000064989) [UNDER SEAL]	439	Patent Owner	Parties and Board
✓	2032	01/17/2024	EX2032 - April 23, 2012 NN9535-3819 Key Result Meeting presentation (produced as NN-OZEM-004341616) [UNDER SEAL]	74	Patent Owner	Parties and Board
✓	2031	01/17/2024	EX2031 - June 9, 2010 End of Phase 2 Meeting Minutes (produced as NN-OZEM-004338845) [UNDER SEAL]	17	Patent Owner	Parties and Board
✓	2030	01/17/2024	EX2030 - May 28, 2010 DPComm presentation (produced as NN-OZEM-004443139) [UNDER SEAL]	26	Patent Owner	Parties and Board
✓	2029	01/17/2024	EX2029 - May 25, 2010 email from Niklas Ohrner to Christine Jensen (produced as NN-OZEM-004443136) [UNDER SEAL]	4	Patent Owner	Parties and Board
✓	2028	01/17/2024	EX2028 - March 17, 2010 Novo Nordisk Diabetes Pipeline Advisory Board Meeting presentation (produced as NN-OZEM-000020275) [UNDER SEAL]	69	Patent Owner	Parties and Board
✓	2027	01/17/2024	EX2027 - March 5, 2010 PK/PD Simulations presentation (produced as NN-OZEM-004442955) [UNDER SEAL]	11	Patent Owner	Parties and Board
✓	2026	01/17/2024	EX2026 - March 5, 2010 email exchange between Daniel Jonker and Christine Jensen (produced as NN-OZEM-004442953) [UNDER SEAL]	3	Patent Owner	Parties and Board
✓	2025	01/17/2024	EX2025 - May 25, 2009 Selection of Doses for Phase 3 presentation (produced as NN-OZEM-004338784) [UNDER SEAL]	25	Patent Owner	Parties and Board
✓	2024	01/17/2024	EX2024 - May 22, 2009 email from Milan Zdravkovic to Christine Jensen et al (produced as NN-OZEM-004449575) [UNDER SEAL]	2	Patent Owner	Parties and Board
✓	2023	01/17/2024	EX2023 - April 22, 2009 email from Lise Brondsted to Christine Jensen et al (produced as NN-OZEM-004470860) [UNDER SEAL]	2	Patent Owner	Parties and Board
✓	2022	01/17/2024	EX2022 - April 22, 2009 NN9535-1821 Key Results Meeting Presentation (produced as NN-OZEM-004470861) [UNDER SEAL]	91	Patent Owner	Parties and Board
✓	2021	01/17/2024	EX2021 - Drug Product: Semaglutide C solution for injection, syringe, Pharmaceutical Development (produced as NN-OZEM-000158851) [UNDER SEAL]	5	Patent Owner	Parties and Board
✓	2020	01/17/2024	EX2020 - Transcript of January 5, 2024 Deposition of William J. Jusko, Ph.D.	10	Patent Owner	Public

✓	Exhibit # ↓	Filing date	Document name	Pages	Filing party	Availability
✓	2019	01/17/2024	EX2019 - Transcript of January 5, 2024 Deposition of William J. Jusko, Ph.D.	185	Patent Owner	Public
✓	2018	01/17/2024	EX2018 - Transcript of December 29, 2023 Deposition of John Bantle, M.D.	169	Patent Owner	Public
✓	2017	01/17/2024	EX2017 - Novo Nordisk Company Announcement (October 10, 2023)	2	Patent Owner	Public
✓	2016	01/17/2024	EX2016 - Mehdj, S., et al., "Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent." Frontiers in Immunology, Vol. 14 (2023)	20	Patent Owner	Public
✓	2015	01/17/2024	EX2015 - Shaman, A., et al., "Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER." Circulation, Vol.145, 575-585 (2022).	11	Patent Owner	Public
✓	2014	01/17/2024	EX2014 - Weeda, E., et al., "Medication adherence to injectable glucagon-like peptide-1 (GLP-1) receptor agonists dosed once weekly vs once daily in patients with type 2 diabetes: A meta-analysis." Int J Clin Pract., Vol.75 (2021)	6	Patent Owner	Public
✓	2013	01/17/2024	EX2013 - Heerspink, H., et al., "Effects of Semaglutide on Albuminuria and Kidney Function in People with Overweight or Obesity With or Without Type 2 Diabetes: Exploratory Analysis from the STEP 1, 2 and 3 Trials." Diabetes Care, Vol.46, Issue 4, 801-810 (2023).	11	Patent Owner	Public
✓	2012	01/17/2024	EX2012 - Rossing, P., et al., "The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease." Nephrol Dial Transplant, Vol.38, 2041-2051 (2023).	11	Patent Owner	Public
✓	2011	01/17/2024	EX2011 - Declaration of George L. Bakris, M.D.	88	Patent Owner	Public
✓	2010	01/17/2024	EX2010 - Expert Declaration of Julio Rosenstock, M.D.	208	Patent Owner	Public
✓	2009	07/06/2023	EX2009 - Declaration of Sayem Osman	5	Patent Owner	Public
✓	2008	07/06/2023	EX2008 - Ozempic®. Prescribing Information (October 2022)	18	Patent Owner	Public
✓	2007	07/06/2023	EX2007 - Excerpt of Novo Nordisk's Initial Responses to Defendants' Initial Invalidation Contentions Regarding U.S. Patent Nos. 8,129,343; 8,536,122; 8,114,833; 8,920,383; 9,775,953; 9,457,154; and 10,335,462. In re: Ozempic (Semaglutide) Patent Litigation, No. 1:22-cv-01040-CFC, (D. Del. Dec. 21, 2022)	3	Patent Owner	Public
✓	2006	07/06/2023	EX2006 - Arrowsmith, J., "Phase II failures: 2008-2010." Nature Reviews, Drug Discovery, Vol. 10 (May 2011).	1	Patent Owner	Public
✓	2005	07/06/2023	EX2005 - Knight, A., "Systematic Reviews of Animal Experiments Demonstrate Poor Contributions Toward Human Healthcare." Reviews on Recent Clinical Trials, Vol.3, Issue 2, 89-96 (2008).	8	Patent Owner	Public
✓	2004	07/06/2023	EX2004 - Miller, M., et al., "Low Viscosity Highly Concentrated Injectable Nonaqueous Suspensions of Lysozyme Microparticles." Langmuir, Author Manuscript (2011). PMC 2011 (Feb 17)	22	Patent Owner	Public
✓	2003	07/06/2023	EX2003 - Excerpt of Amended Joint Claim Construction Chart. In re: Ozempic (Semaglutide) Patent Litigation, No. 1:22-cv-01040-CFC, Dkt. 101 (D. Del. May 23, 2023).	4	Patent Owner	Public
✓	2002	07/06/2023	EX2002 - U.S. Patent No. 9,764,003	25	Patent Owner	Public
✓	2001	07/06/2023	EX2001 - U.S. Patent No. 9,764,003 File History.	563	Patent Owner	Public
✓	1325	05/22/2024	Exhibit 1325 - Symlin	2	Petitioner	Public
✓	1323	05/22/2024	Exhibit 1323 - SEALED NN-OZEM-004426808	49	Petitioner	Parties and Board
✓	1321	05/22/2024	Exhibit 1321 - Bloomberg	3	Petitioner	Public
✓	1320	05/22/2024	Exhibit 1320 - NCT657	6	Petitioner	Public
✓	1319	05/22/2024	Exhibit 1319 - NCT271	11	Petitioner	Public
✓	1318	05/22/2024	Exhibit 1318 - NCT723	3	Petitioner	Public
✓	1317	05/22/2024	Exhibit 1317 - NCT232	4	Petitioner	Public

✓	Exhibit # ↓	Filing date	Document name	Pages	Filing party	Availability
✓	1316	05/22/2024	Exhibit 1316 - NCT058	6	Petitioner	Public
✓	1315	05/22/2024	Exhibit 1315 - Colhoun	6	Petitioner	Public
✓	1314	05/22/2024	Exhibit 1314 - SEALED Vellturo Dep	37	Petitioner	Parties and Board
✓	1313	05/22/2024	Exhibit 1313 - Rosenstock Dep	242	Petitioner	Public
✓	1312	05/22/2024	Exhibit 1312 - SEALED Jensen Dep	117	Petitioner	Parties and Board
✓	1311	05/22/2024	Exhibit 1311 - SEALED Flint Dep	120	Petitioner	Parties and Board
✓	1310	05/22/2024	Exhibit 1310 - Bakris Dep Tr	72	Petitioner	Public
✓	1308	05/22/2024	Exhibit 1308 - SEALED McDuff Decl	73	Petitioner	Parties and Board
✓	1307	05/22/2024	Exhibit 1307 - Coca CV	42	Petitioner	Public
✓	1306	05/22/2024	Exhibit 1306 - Coca Decl	82	Petitioner	Public
✓	1305	05/22/2024	Exhibit 1305 - Schwartzbard CV	9	Petitioner	Public
✓	1304	05/22/2024	Exhibit 1304 - Schwartzbard Decl	108	Petitioner	Public
✓	1303	05/22/2024	Exhibit 1303 - Spiegel CV	52	Petitioner	Public
✓	1302	05/22/2024	Exhibit 1302 - Speigel Decl	122	Petitioner	Public
✓	1301	05/22/2024	Exhibit 1301 - Jusko Decl	170	Petitioner	Public
✓	1300	05/22/2024	Exhibit 1300 - Bantle Decl	187	Petitioner	Public
✓	1299	05/22/2024	Exhibit 1299 - Wheeler	10	Petitioner	Public
✓	1298	05/22/2024	Exhibit 1298 - Perkovic 2019	12	Petitioner	Public
✓	1297	05/22/2024	Exhibit 1297 - Herrington	11	Petitioner	Public
✓	1296	05/22/2024	Exhibit 1296 - 032 App Pros History Excerpts	39	Petitioner	Public
✓	1295	05/22/2024	Exhibit 1295 - 032 App	16	Petitioner	Public
✓	1294	05/22/2024	Exhibit 1294 - Mima	5	Petitioner	Public
✓	1293	05/22/2024	Exhibit 1293 - 43rd Orange Book	4	Petitioner	Public
✓	1292	05/22/2024	Exhibit 1292 - Holman	13	Petitioner	Public
✓	1291	05/22/2024	Exhibit 1291 - Rosenstock 1986	17	Petitioner	Public
✓	1290	05/22/2024	Exhibit 1290 - Chatzigeorgiou	14	Petitioner	Public
✓	1289	05/22/2024	Exhibit 1289 - Rees	12	Petitioner	Public
✓	1287	05/22/2024	Exhibit 1287 - Kendall	9	Petitioner	Public
✓	1285	05/22/2024	Exhibit 1285 - Feb. 2, 2012 Novo Nordisk Earnings Call	18	Petitioner	Public
✓	1284	05/22/2024	Exhibit 1284 - Marre	11	Petitioner	Public
✓	1283	05/22/2024	Exhibit 1283 - Novo Nordisk 2010-2011 Pipeline	3	Petitioner	Public
✓	1282	05/22/2024	Exhibit 1282 - Novo Nordisk Form 6-K (May 1, 2009)	29	Petitioner	Public
✓	1280	05/22/2024	Exhibit 1280 - Knight 2008	14	Petitioner	Public
✓	1279	05/22/2024	Exhibit 1279 - Califf	10	Petitioner	Public
✓	1278	05/22/2024	Exhibit 1278 - De Block	3	Petitioner	Public

✓	Exhibit # ↓	Filing date	Document name	Pages	Filing party	Availability
✓	1276	05/22/2024	Exhibit 1276 - Diabetes Care 2024	40	Petitioner	Public
✓	1275	05/22/2024	Exhibit 1275 - DeFronzo	11	Petitioner	Public
✓	1274	05/22/2024	Exhibit 1274 - Diabetes Prevention Program (DPP)	4	Petitioner	Public
✓	1273	05/22/2024	Exhibit 1273 - FDA	25	Petitioner	Public
✓	1272	05/22/2024	Exhibit 1272 - Diabetes Care 2010	51	Petitioner	Public
✓	1271	05/22/2024	Exhibit 1271 - Diabetes Care 2019	11	Petitioner	Public
✓	1270	05/22/2024	Exhibit 1270 - UKPDS34	12	Petitioner	Public
✓	1269	05/22/2024	Exhibit 1269 - King	6	Petitioner	Public
✓	1268	05/22/2024	Exhibit 1268 - UKPDS 38	11	Petitioner	Public
✓	1267	05/22/2024	Exhibit 1267 - UKPDS 33.pdf	18	Petitioner	Public
✓	1266	05/22/2024	Exhibit 1266 - Whelton	111	Petitioner	Public
✓	1265	05/22/2024	Exhibit 1265 - Invokana Label	50	Petitioner	Public
✓	1264	05/22/2024	Exhibit 1264 - Jardiance Label (9-23)	50	Petitioner	Public
✓	1263	05/22/2024	Exhibit 1263 - Victoza Label (7-2023)	40	Petitioner	Public
✓	1262	05/22/2024	Exhibit 1262 - Trulicity Label (11-2022)	58	Petitioner	Public
✓	1261	05/22/2024	Exhibit 1261 - Fed Reg	3	Petitioner	Public
✓	1260	05/22/2024	Exhibit 1260 - FDA Background	38	Petitioner	Public
✓	1259	05/22/2024	Exhibit 1259 - FDA Guidance 2008	8	Petitioner	Public
✓	1258	05/22/2024	Exhibit 1258 - Blaha Transcript	77	Petitioner	Public
✓	1257	05/22/2024	Exhibit 1257 - Braunwald's	24	Petitioner	Public
✓	1256	05/22/2024	Exhibit 1256 - Southwell	2	Petitioner	Public
✓	1255	05/22/2024	Exhibit 1255 - Bucher	9	Petitioner	Public
✓	1254	05/22/2024	Exhibit 1254 - Parks	4	Petitioner	Public
✓	1253	05/22/2024	Exhibit 1253 - Reiger	8	Petitioner	Public
✓	1252	05/22/2024	Exhibit 1252 - Ravassa	8	Petitioner	Public
✓	1251	05/22/2024	Exhibit 1251 - Astrup	12	Petitioner	Public
✓	1250	05/22/2024	Exhibit 1250 - CANVAS	13	Petitioner	Public
✓	1249	05/22/2024	Exhibit 1249 - Zinman	12	Petitioner	Public
✓	1248	05/22/2024	Exhibit 1248 - Gerstein	10	Petitioner	Public
✓	1247	05/22/2024	Exhibit 1247 - Marso	12	Petitioner	Public
✓	1246	05/22/2024	Exhibit 1246 - Smilowitz	8	Petitioner	Public
✓	1245	05/22/2024	Exhibit 1245 - Sokos	6	Petitioner	Public
✓	1244	05/22/2024	Exhibit 1244 - Sivertsen	14	Petitioner	Public
✓	1243	05/22/2024	Exhibit 1243 - Ratner	10	Petitioner	Public
✓	1242	05/22/2024	Exhibit 1242 - Marso	4	Petitioner	Public
✓	1241	05/22/2024	Exhibit 1241 - Ussher	29	Petitioner	Public

✓	Exhibit # ↓	Filing date	Document name	Pages	Filing party	Availability
✓	1240	05/22/2024	Exhibit 1240 - Mells	11	Petitioner	Public
✓	1239	05/22/2024	Exhibit 1239 - Sesti	4	Petitioner	Public
✓	1238	05/22/2024	Exhibit 1238 - Varanasi	6	Petitioner	Public
✓	1237	05/22/2024	Exhibit 1237 - Mannucci	8	Petitioner	Public
✓	1236	05/22/2024	Exhibit 1236 - Okerson	6	Petitioner	Public
✓	1235	05/22/2024	Exhibit 1235 - Horton	7	Petitioner	Public
✓	1234	05/22/2024	Exhibit 1234 - Noyan-Ashraf	9	Petitioner	Public
✓	1233	05/22/2024	Exhibit 1233 - Ban	11	Petitioner	Public
✓	1232	05/22/2024	Exhibit 1232 - Hirata	6	Petitioner	Public
✓	1231	05/22/2024	Exhibit 1231 - Bose	6	Petitioner	Public
✓	1230	05/22/2024	Exhibit 1230 - Nikolaidis	4	Petitioner	Public
✓	1229	05/22/2024	Exhibit 1229 - Nystrom	7	Petitioner	Public
✓	1228	05/22/2024	Exhibit 1228 - Bagio	27	Petitioner	Public
✓	1227	05/22/2024	Exhibit 1227 - Kernan	11	Petitioner	Public
✓	1226	05/22/2024	Exhibit 1226 - Lathief	15	Petitioner	Public
✓	1225	05/22/2024	Exhibit 1225 - Pignone	8	Petitioner	Public
✓	1224	05/22/2024	Exhibit 1224 - Arnett	51	Petitioner	Public
✓	1223	05/22/2024	Exhibit 1223 - Emdin	13	Petitioner	Public
✓	1222	05/22/2024	Exhibit 1222 - Sabatine	10	Petitioner	Public
✓	1221	05/22/2024	Exhibit 1221 - Sabatine	10	Petitioner	Public
✓	1220	05/22/2024	Exhibit 1220 - Giugliano	12	Petitioner	Public
✓	1219	05/22/2024	Exhibit 1219 - Grundy	62	Petitioner	Public
✓	1218	05/22/2024	Exhibit 1218 - Fox	28	Petitioner	Public
✓	1217	05/22/2024	Exhibit 1217 - Rawshani	12	Petitioner	Public
✓	1216	05/22/2024	Exhibit 1216 - Hess	12	Petitioner	Public
✓	1215	05/22/2024	Exhibit 1215 - Orasanu	8	Petitioner	Public
✓	1214	05/22/2024	Exhibit 1214 - Standl	14	Petitioner	Public
✓	1213	05/22/2024	Exhibit 1213 - Gore	7	Petitioner	Public
✓	1212	05/22/2024	Exhibit 1212 - Rawshani	12	Petitioner	Public
✓	1211	05/22/2024	Exhibit 1211 - USRE46363	15	Petitioner	Public
✓	1210	05/22/2024	Exhibit 1210 - Walker	22	Petitioner	Public
✓	1209	05/22/2024	Exhibit 1209 - WO2005049061A2	43	Petitioner	Public
✓	1208	05/22/2024	Exhibit 1208 - MPEP	2	Petitioner	Public
✓	1207	05/22/2024	Exhibit 1207 - Weintraub	5	Petitioner	Public
✓	1206	05/22/2024	Exhibit 1206 - Wegovy label - 7.2023	43	Petitioner	Public
✓	1205	05/22/2024	Exhibit 1205 - US10357616	23	Petitioner	Public

✓	Exhibit # ↓	Filing date	Document name	Pages	Filing party	Availability
✓	1204	05/22/2024	Exhibit 1204 - US10220155	6	Petitioner	Public
✓	1203	05/22/2024	Exhibit 1203 - US11311679	19	Petitioner	Public
✓	1202	05/22/2024	Exhibit 1202 - US11446443	12	Petitioner	Public
✓	1201	05/22/2024	Exhibit 1201 - US9486588	16	Petitioner	Public
✓	1200	05/22/2024	Exhibit 1200 - US9775953	15	Petitioner	Public
✓	1199	05/22/2024	Exhibit 1199 - US9861757	22	Petitioner	Public
✓	1198	05/22/2024	Exhibit 1198 - US11097063	6	Petitioner	Public
✓	1197	05/22/2024	Exhibit 1197 - US10376652	20	Petitioner	Public
✓	1196	05/22/2024	Exhibit 1196 - US9616180	20	Petitioner	Public
✓	1195	05/22/2024	Exhibit 1195 - US9687611	12	Petitioner	Public
✓	1194	05/22/2024	Exhibit 1194 - US8920383	14	Petitioner	Public
✓	1193	05/22/2024	Exhibit 1193 - US8672898	18	Petitioner	Public
✓	1192	05/22/2024	Exhibit 1192 - US9132239	8	Petitioner	Public
✓	1191	05/22/2024	Exhibit 1191 - US9457154	23	Petitioner	Public
✓	1190	05/22/2024	Exhibit 1190 - Earnings Call	34	Petitioner	Public
✓	1189	05/22/2024	Exhibit 1189 - Gilbert	9	Petitioner	Public
✓	1188	05/22/2024	Exhibit 1188 - US9108002	19	Petitioner	Public
✓	1187	05/22/2024	Exhibit 1187 - US8579869	14	Petitioner	Public
✓	1186	05/22/2024	Exhibit 1186 - Gilbert	4	Petitioner	Public
✓	1185	05/22/2024	Exhibit 1185 - Track Drugs	21	Petitioner	Public
✓	1184	05/22/2024	Exhibit 1184	147	Petitioner	Public
✓	1183	05/22/2024	Exhibit 1183 - US7762994	14	Petitioner	Public
✓	1182	05/22/2024	Exhibit 1182 - Ingram	5	Petitioner	Public
✓	1181	05/22/2024	Exhibit 1181 - MedlinePlus - Type 2 Diabetes 2.10.23	12	Petitioner	Public
✓	1180	05/22/2024	Exhibit 1180 - David and Stewart	12	Petitioner	Public
✓	1179	05/22/2024	Exhibit 1179 - Corr	6	Petitioner	Public
✓	1178	05/22/2024	Exhibit 1178 - Novo Nordisk - Annual Report 2007	124	Petitioner	Public
✓	1177	05/22/2024	Exhibit 1177 - Novo Nordisk - Annual Report 2023	112	Petitioner	Public
✓	1176	05/22/2024	Exhibit 1176 - McPhillips	4	Petitioner	Public
✓	1175	05/22/2024	Exhibit 1175 - FDA FAQ	2	Petitioner	Public
✓	1174	05/22/2024	Exhibit 1174 - FDA FAQ	4	Petitioner	Public
✓	1173	05/22/2024	Exhibit 1173 - Gordon	3	Petitioner	Public
✓	1172	05/22/2024	Exhibit 1172 - Khan	3	Petitioner	Public
✓	1171	05/22/2024	Exhibit 1171 - McDuff	5	Petitioner	Public
✓	1170	05/22/2024	Exhibit 1170 - Correa	7	Petitioner	Public
✓	1169	05/22/2024	Exhibit 1169 - US8684969	13	Petitioner	Public

✓	Exhibit # ↓	Filing date	Document name	Pages	Filing party	Availability
✓	1168	05/22/2024	Exhibit 1168 - US6899699	15	Petitioner	Public
✓	1167	05/22/2024	Exhibit 1167 - Amend compl	44	Petitioner	Public
✓	1166	05/22/2024	Exhibit 1166 - 42nd Orange Book	3	Petitioner	Public
✓	1165	05/22/2024	Exhibit 1165 - 41st Orange Book	3	Petitioner	Public
✓	1164	05/22/2024	Exhibit 1164 - Kanbay	13	Petitioner	Public
✓	1163	05/22/2024	Exhibit 1163 - Gutzwiller	9	Petitioner	Public
✓	1162	05/22/2024	Exhibit 1162 - Rizzo	10	Petitioner	Public
✓	1161	05/22/2024	Exhibit 1161 - Zeeuw	12	Petitioner	Public
✓	1160	05/22/2024	Exhibit 1160 - Perkovic	7	Petitioner	Public
✓	1159	05/22/2024	Exhibit 1159 - McGuire	10	Petitioner	Public
✓	1158	05/22/2024	Exhibit 1158 - Novo Press Release	3	Petitioner	Public
✓	1157	05/22/2024	Exhibit 1157 - Davidson	11	Petitioner	Public
✓	1156	05/22/2024	Exhibit 1156 - Jacobsen	8	Petitioner	Public
✓	1155	05/22/2024	Exhibit 1155 - Bode	9	Petitioner	Public
✓	1154	05/22/2024	Exhibit 1154 - Zepbound	39	Petitioner	Public
✓	1153	05/22/2024	Exhibit 1153 - Edwards 2004	5	Petitioner	Public
✓	1152	05/22/2024	Exhibit 1152 - Kodera	14	Petitioner	Public
✓	1151	05/22/2024	Exhibit 1151 - Liu 2010	10	Petitioner	Public
✓	1150	05/22/2024	Exhibit 1150 - Park 2007	12	Petitioner	Public
✓	1149	05/22/2024	Exhibit 1149 - Gutzwiller	7	Petitioner	Public
✓	1148	05/22/2024	Exhibit 1148 - Yu	11	Petitioner	Public
✓	1147	05/22/2024	Exhibit 1147 - Vollenweider	2	Petitioner	Public
✓	1146	05/22/2024	Exhibit 1146 - KDOQI 2007	143	Petitioner	Public
✓	1145	05/22/2024	Exhibit 1145 - Pyram	10	Petitioner	Public
✓	1144	05/22/2024	Exhibit 1144 - Holz	13	Petitioner	Public
✓	1143	05/22/2024	Exhibit 1143 - James	14	Petitioner	Public
✓	1142	05/22/2024	Exhibit 1142 - Radbill	9	Petitioner	Public
✓	1141	05/22/2024	Exhibit 1141 - Preuss	11	Petitioner	Public
✓	1140	05/22/2024	Exhibit 1140 - Goland Dep	104	Petitioner	Public
✓	1139	05/22/2024	Exhibit 1139 - Lorenz	8	Petitioner	Public
✓	1138	05/22/2024	Exhibit 1138 - Holst 2004b	8	Petitioner	Public
✓	1137	05/22/2024	Exhibit 1137 - Bhansali	5	Petitioner	Public
✓	1136	05/22/2024	Exhibit 1136 - Harrisons	44	Petitioner	Public
✓	1135	05/22/2024	Exhibit 1135 - 40th Orange Book	2	Petitioner	Public
✓	1134	05/22/2024	Exhibit 1134 - 39th Orange Book	3	Petitioner	Public
✓	1133	05/22/2024	Exhibit 1133 - 37th Orange Book	2	Petitioner	Public

✓	Exhibit # ↓	Filing date	Document name	Pages	Filing party	Availability
✓	1132	05/22/2024	Exhibit 1132 - Amori	13	Petitioner	Public
✓	1131	05/22/2024	Exhibit 1131 - Form 6K 2011	37	Petitioner	Public
✓	1130	05/22/2024	Exhibit 1130 - Novo Nordisk Annual Report 2011	116	Petitioner	Public
✓	1129	05/22/2024	Exhibit 1129 - Cecil	39	Petitioner	Public
✓	1128	05/22/2024	Exhibit 1128 - Proposed order	3	Petitioner	Public
✓	1127	05/22/2024	Exhibit 1127 - CLAIM CONSTRUCTION ORDER	8	Petitioner	Public
✓	1126	05/22/2024	Exhibit 1126 - Pratley	11	Petitioner	Public
✓	1125	05/22/2024	Exhibit 1125 - Pi-Sunyer	12	Petitioner	Public
✓	1124	05/22/2024	Exhibit 1124 - GRADE	12	Petitioner	Public
✓	1122	05/22/2024	Exhibit 1122 - ADA Standards 2023	18	Petitioner	Public
✓	1121	05/22/2024	Exhibit 1121 - 833 patent	22	Petitioner	Public
✓	1120	05/22/2024	Exhibit 1120 - Saxenda Orange Book	4	Petitioner	Public
✓	1119	05/22/2024	Exhibit 1119 - Trulicity label	62	Petitioner	Public
✓	1118	05/22/2024	Exhibit 1118	29	Petitioner	Public
✓	1117	05/22/2024	Exhibit 1117 - Disapproval	5	Petitioner	Public
✓	1116	05/22/2024	Exhibit 1116 - Mounjaro label	28	Petitioner	Public
✓	1115	05/22/2024	Exhibit 1115 - CDC Report	15	Petitioner	Public
✓	1114	05/22/2024	Exhibit 1114 - Buse	9	Petitioner	Public
✓	1113	05/22/2024	Exhibit 1113 - Skrivanek	9	Petitioner	Public
✓	1112	05/22/2024	Exhibit 1112 - Ostawal	28	Petitioner	Public
✓	1111	05/22/2024	Exhibit 1111 - Madsbad	16	Petitioner	Public
✓	1110	05/22/2024	Exhibit 1110 - Karagiannis	17	Petitioner	Public
✓	1109	05/22/2024	Exhibit 1109 - Grunberger	8	Petitioner	Public
✓	1108	05/22/2024	Exhibit 1108 - White	5	Petitioner	Public
✓	1107	05/22/2024	Exhibit 1107 - Wegovy Orange book	3	Petitioner	Public
✓	1106	05/22/2024	Exhibit 1106 - Wegovy label	44	Petitioner	Public
✓	1105	05/22/2024	Exhibit 1105 - Victoza Orange Book	2	Petitioner	Public
✓	1104	05/22/2024	Exhibit 1104 - Vahl	12	Petitioner	Public
✓	1103	05/22/2024	Exhibit 1103 - Saxenda label	40	Petitioner	Public
✓	1102	05/22/2024	Exhibit 1102 - Rubio-Herrera	17	Petitioner	Public
✓	1101	05/22/2024	Exhibit 1101 - Ozempic Orange Book	5	Petitioner	Public
✓	1100	05/22/2024	Exhibit 1100 - Jose	12	Petitioner	Public
✓	1099	05/22/2024	Exhibit 1099 - Garber 2011b	6	Petitioner	Public
✓	1098	05/22/2024	Exhibit 1098 - Garber 2011a	9	Petitioner	Public
✓	1097	05/22/2024	Exhibit 1097 - Garber 2009	9	Petitioner	Public
✓	1096	05/22/2024	Exhibit 1096 - Astrup	11	Petitioner	Public

✓	Exhibit # ↓	Filing date	Document name	Pages	Filing party	Availability
✓	1093	12/18/2023	Beel Declaration	6	Petitioner	Public
✓	1092	12/18/2023	Anstaett Declaration	8	Petitioner	Public
✓	1091	12/18/2023	Bloodworth Declaration	12	Petitioner	Public
✓	1090	08/10/2023	Exhibit 1090	129	Petitioner	Public
✓	1089	08/10/2023	Exhibit 1089	8	Petitioner	Public
✓	1088	08/10/2023	Exhibit 1088	134	Petitioner	Public
✓	1087	03/16/2023	003 file history excerpt	8	Petitioner	Public
✓	1086	03/16/2023	Last update posted definition	1	Petitioner	Public
✓	1085	03/16/2023	J Med Chem	34	Petitioner	Public
✓	1084	03/16/2023	ICH 2001	10	Petitioner	Public
✓	1083	03/16/2023	Transfer order	5	Petitioner	Public
✓	1082	03/16/2023	Scheduling order	38	Petitioner	Public
✓	1081	03/16/2023	Ozempic label 2022	63	Petitioner	Public
✓	1080	03/16/2023	NCT490	6	Petitioner	Public
✓	1079	03/16/2023	NCT115	5	Petitioner	Public
✓	1078	03/16/2023	US20040102486	9	Petitioner	Public
✓	1077	03/16/2023	Harvard Award webpage	4	Petitioner	Public
✓	1076	03/16/2023	ClinicalTrials webpage	4	Petitioner	Public
✓	1075	03/16/2023	US7022674	21	Petitioner	Public
✓	1074	03/16/2023	W0098	27	Petitioner	Public
✓	1073	03/16/2023	US6458924	129	Petitioner	Public
✓	1072	03/16/2023	US5164366	18	Petitioner	Public
✓	1071	03/16/2023	US6284727	43	Petitioner	Public
✓	1070	03/16/2023	Modern Pharmaceuticals 1996	53	Petitioner	Public
✓	1069	03/16/2023	Remington 20th ed	62	Petitioner	Public
✓	1068	03/16/2023	US8129343	70	Petitioner	Public
✓	1067	03/16/2023	US8536122	70	Petitioner	Public
✓	1066	03/16/2023	Knudsen 2010b	8	Petitioner	Public
✓	1065	03/16/2023	Tasneem 2012	12	Petitioner	Public
✓	1064	03/16/2023	Monami 2012	8	Petitioner	Public
✓	1063	03/16/2023	Kirillova 2012	8	Petitioner	Public
✓	1062	03/16/2023	Zarin 2011	9	Petitioner	Public
✓	1061	03/16/2023	US20110166321	131	Petitioner	Public
✓	1060	03/16/2023	W0193	99	Petitioner	Public
✓	1059	03/16/2023	Murphy 2012	10	Petitioner	Public
✓	1058	03/16/2023	Blonde 2012	13	Petitioner	Public

✓	Exhibit # ↓	Filing date	Document name	Pages	Filing party	Availability
✓	1057	03/16/2023	W0328	96	Petitioner	Public
✓	1056	03/16/2023	US518666	24	Petitioner	Public
✓	1055	03/16/2023	Landersdorfer 2011b	18	Petitioner	Public
✓	1054	03/16/2023	Landersdorfer 2011a	11	Petitioner	Public
✓	1053	03/16/2023	Moller 2011	13	Petitioner	Public
✓	1052	03/16/2023	Madsbad 2011	14	Petitioner	Public
✓	1051	03/16/2023	Landersdorfer 2008	32	Petitioner	Public
✓	1050	03/16/2023	Garber	7	Petitioner	Public
✓	1049	03/16/2023	ICH 1994	6	Petitioner	Public
✓	1048	03/16/2023	FDA Exposure Response 2003	28	Petitioner	Public
✓	1047	03/16/2023	Tamimi 2009	7	Petitioner	Public
✓	1046	03/16/2023	Yun 2006	7	Petitioner	Public
✓	1045	03/16/2023	Shargel	115	Petitioner	Public
✓	1044	03/16/2023	Rohatagi	10	Petitioner	Public
✓	1043	03/16/2023	US20040102486	9	Petitioner	Public
✓	1042	03/16/2023	W0457	50	Petitioner	Public
✓	1041	03/16/2023	W0136	50	Petitioner	Public
✓	1040	03/16/2023	Vilsboll 2009	7	Petitioner	Public
✓	1039	03/16/2023	Victoza PDR	12	Petitioner	Public
✓	1038	03/16/2023	Seino 2008	8	Petitioner	Public
✓	1037	03/16/2023	Nielsen 2004	12	Petitioner	Public
✓	1036	03/16/2023	Mojsov 1987	4	Petitioner	Public
✓	1035	03/16/2023	Lund 2011	12	Petitioner	Public
✓	1034	03/16/2023	Knudsen patent	137	Petitioner	Public
✓	1033	03/16/2023	Knudsen 2010	42	Petitioner	Public
✓	1032	03/16/2023	Knudsen 2004	7	Petitioner	Public
✓	1031	03/16/2023	Knudsen 2001	9	Petitioner	Public
✓	1030	03/16/2023	Kim 2007	7	Petitioner	Public
✓	1029	03/16/2023	Jimenez-Solem 2010	8	Petitioner	Public
✓	1028	03/16/2023	Holst 2004	8	Petitioner	Public
✓	1027	03/16/2023	Holst 1987	6	Petitioner	Public
✓	1026	03/16/2023	Harrison's 2008	32	Petitioner	Public
✓	1025	03/16/2023	Glaesner 2010	10	Petitioner	Public
✓	1024	03/16/2023	Drucker 2006	10	Petitioner	Public
✓	1023	03/16/2023	Drucker 2003	12	Petitioner	Public
✓	1022	03/16/2023	Drab 2010	16	Petitioner	Public

✓	Exhibit # ↓	Filing date	Document name	Pages	Filing party	Availability
✓	1021	03/16/2023	Byetta label 2009	34	Petitioner	Public
✓	1020	03/16/2023	Bydureon label 2012	27	Petitioner	Public
✓	1019	03/16/2023	Bell 1983	3	Petitioner	Public
✓	1018	03/16/2023	Banting 1922	16	Petitioner	Public
✓	1017	03/16/2023	US5512549	15	Petitioner	Public
✓	1016	03/16/2023	US20070010424	22	Petitioner	Public
✓	1015	03/16/2023	W0537	76	Petitioner	Public
✓	1014	03/16/2023	NCT773	14	Petitioner	Public
✓	1013	03/16/2023	NCT657	41	Petitioner	Public
✓	1012	03/16/2023	Lovshin 2009	8	Petitioner	Public
✓	1011	03/16/2023	WQ421	72	Petitioner	Public
✓	1008	03/16/2023	Dalby CV	22	Petitioner	Public
✓	1007	03/16/2023	Dalby Decl	115	Petitioner	Public
✓	1006	03/16/2023	Jusko CV	24	Petitioner	Public
✓	1005	03/16/2023	Jusko Decl	132	Petitioner	Public
✓	1004	03/16/2023	Bantle CV	12	Petitioner	Public
✓	1003	03/16/2023	Bantle Decl	178	Petitioner	Public
✓	1002	03/16/2023	462 file history	369	Petitioner	Public
✓	1001	03/16/2023	US10335462	25	Petitioner	Public

> Real party

> Counsel

> Payments